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Abstract 
This archival-data study assessed the potentially complementary mechanisms of action of 
sibutramine and behavior therapy (also known as lifestyle modification) believed to be 
responsible for the greater weight loss observed with combining the two approaches than 
with either approach alone. One hundred and seventy-one subjects were randomly 
assigned to receive 15 mg of sibutramine per day alone, delivered by a primary-care 
provider in five brief office visits; behavior therapy alone, delivered by a psychologist in 
18 group sessions; and sibutramine (15 mg/day) plus 18 group sessions of behavior 
therapy (i.e., combined therapy). Mixed effects linear model analysis was used to 
compare changes in scores among the groups on the Eating Behavior Inventory and on 
visual analogue scales of appetite. Most of the findings were either significant or in the 
expected direction. Subjects who received sibutramine alone and behavior therapy alone 
displayed improvements principally in appetite control and eating behavior, respectively. 
By comparison, those who received combined therapy displayed improvements in both 
areas. These results provide evidence that sibutramine and behavior therapy work 
additively to produce greater weight loss than either therapy alone. Furthermore, they 
underscore the importance of prescribing weight loss medications in combination with 
lifestyle modification, an approach that may be facilitated through the integration of 
behavioral-health providers within primary care. 
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Chapter One: Introduction 
 Statement of the Problem 
 Obesity has reached epidemic proportions in the United States. Approximately 
66% of adults are classified as overweight, of whom 32% are obese (Ogden et al., 2006). 
The overall health care costs attributable to obesity increased from an estimated $99.2 
billion per year in 1995 (Greenway et al., 1999) to an estimated $117 billion per year in 
2004 (Stein & Colditz, 2004). The marked rise in obesity is alarming because of the array 
of adverse medical and psychosocial consequences that often impair the physical and 
emotional functioning of obese persons. Obesity increases the risk of developing a 
variety of medical conditions, including hypertension, coronary artery disease, 
hypercholesterolemia, type 2 diabetes, osteoarthritis, various cancers, sleep apnea, 
gallbladder disease, and orthopedic complications (Bray, 2004; Brown, Fujioka, Wilson, 
& Woodworth, 2009; Field, Barnoya, & Colditz, 2002). A considerable amount of 
psychopathology also is found among obese patients who seek professional assistance 
with weight loss. Depression, binge-eating disorder, body image dissatisfaction, and 
impaired health-related quality of life are prevalent in this population (de Zwaan, 2001; 
Fitzgibbon, Stolley, & Kirschenbaum, 1993; Nauta, Hospers, & Jansen, 2001; Sarwer & 
Thompson, 2002; Wadden, Womble, Stunkard, & Anderson, 2002). In addition, obese 
individuals are targets of widespread prejudice and discrimination (Sarlio-Lahteenkorva, 
2001; Wadden et al., 2002; Wang, Brownell, & Wadden, 2004).  
 Several approaches to weight loss have been developed, such as a variety of self-
directed diets and commercial programs. Unfortunately, many of these approaches have 
not been subjected to randomized controlled trials and, thus, lack empirical support (Tsai 
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& Wadden, 2005; Womble, Wang, & Wadden, 2002). Two approaches that have been 
empirically validated for the management of obesity include behavior therapy (Foster, 
Makris, & Bailer, 2005; Wadden, Crerand, & Brock, 2005) and pharmacotherapy (James 
et al., 2000; Sjostrom et al., 1998; Yanovski & Yanovski, 2002). Behavior therapy 
promotes weight loss by facilitating the adoption of healthy eating and physical activity 
behaviors, whereas pharmacotherapy targets weight loss through the use of medications. 
At the time of the current study, two pharmacological agents – sibutramine (Meridia; 
Abbot Laboratories, North Chicago, IL) and orlistat (Xenical; Roche Laboratories, 
Burlington, NC) – were approved by the U.S. Food and Drug Administration (FDA) for 
the long-term management of obesity. Whereas orlistat remains on the market, 
sibutramine has since been removed because of its association with adverse 
cardiovascular events (James et al., 2010).  
To achieve optimal weight control, the National Heart, Lung, and Blood Institute 
(NHLBI) (1998) recommends the use of pharmacotherapy as an adjunct to a 
comprehensive program of diet, exercise, and behavior therapy. The combination of 
sibutramine and behavior therapy (which includes diet and exercise), in particular, has 
been found to produce clinically significant weight loss that exceeds the losses achieved 
with either sibutramine or behavior therapy alone (Wadden, Berkowitz, et al., 2005). The 
success of this combination is believed to be attributable to the additive effects of 
sibutramine and behavior therapy (Wadden, Butryn, & Wilson, 2007). Sibutramine, a 
serotonin-norepinephrine reuptake inhibitor, appears to modify biological variables 
related to appetite, such as levels of hunger and satiation (Bray, 2002). These actions 
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appear to reduce patients’ responsiveness or vulnerabilities to food cues. Behavior 
therapy teaches patients to control external eating-related cues by such methods as storing 
foods out of sight, avoiding high-risk situations (e.g., fast-food restaurants), and limiting 
activities while eating (e.g., watching television). It also provides strategies to control 
eating in response to social or emotional cues (Foster et al., 2005; Wadden, Crerand, et 
al., 2005). Evidence suggests that sibutramine and behavior therapy have these separate 
effects (Bray, 2002; Foster et al., 2005; Wadden, Crerand, et al., 2005). However, no 
study has assessed the potentially complementary mechanisms of action of sibutramine 
and behavior therapy in a trial that examines these therapies separately and combined.    
Purpose of the Study 
 The purpose of the current archival-data study was to examine changes in appetite 
and eating behavior associated with the provision of sibutramine, behavior therapy, and 
their combination. This investigation utilized data that were collected as part of a 
randomized controlled trial by Wadden, Berkowitz, and colleagues (2005), as previously 
described. Subjects who received the combination of therapies were expected to display 
significantly better appetite control and more appropriate eating behavior than subjects 
who received either therapy alone. Improvements in both appetite control and eating 
behavior were predicted to account for the greater weight loss observed with combined 
therapy. The results of this study are expected to provide evidence for these 
complementary mechanisms of action and to improve the quality of care provided to 
obese patients in primary care.  
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Relevance to Cognitive Behavior Therapy 
Pharmacotherapy and behavior therapy are two established approaches to the 
management of obesity. While pharmacotherapy is rooted in the medical model, behavior 
therapy is based on principles of learning theory (Foster et al., 2005; Wadden, Crerand, et 
al., 2005). Behavior therapy assumes that eating behaviors are conditioned phenomena 
that are amenable to modification through the application of behavioral principles and 
techniques. Accordingly, classical conditioning and operant conditioning serve important 
functions in treatment (Foster et al., 2005; Wadden, Crerand, et al., 2005). The principle 
of classical conditioning holds that stimuli that are repeatedly presented before or 
simultaneously with a particular behavior become associated with that behavior (Pavlov, 
1927). The more often two events are paired, the stronger the association becomes, such 
that the presence of one event automatically triggers the other. For example, eating is 
often associated with watching television. After repeatedly pairing the act of eating with 
watching television, simply turning on the television may trigger a craving to eat. Eating 
may be triggered by a single cue, but it is more typically triggered by several events 
linked together (Brownell, 2004). Repeatedly pairing eating with different stimuli impairs 
weight control since these latter events become linked with the consumption of food. 
The principle of operant conditioning holds that the frequency at which a given 
behavior occurs is influenced by its consequences (or reinforcement value) (Skinner, 
1953). Behaviors that are rewarded with pleasant consequences are likely to be repeated, 
while those that yield aversive consequences are likely to be extinguished. For example, 
if an obese man were to experience joy from eating ice cream, then he likely would have 
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difficulty modifying this behavior because of the positive reinforcement that is gained 
from eating ice cream. If he were to experience soreness and exhaustion after exercising, 
then he likely would feel compelled to abandon his exercise efforts in order to avoid 
these unpleasant consequences. In total, identifying the antecedents and consequences 
that maintain unhealthy eating and physical activity behavior (through a functional 
analysis of behavior) represents a central goal in behavior therapy (Foster et al., 2005; 
Wadden, Crerand, et al., 2005).  
While the principal goal of behavior therapy is to promote healthful changes in 
eating and physical activity behavior, maladaptive cognitions related to weight 
management are also addressed in treatment. Cognitions that commonly undermine 
efforts to lose weight tend to be dichotomous, catastrophic, and overgeneralized 
(Brownell, 2004; Wadden, Crerand, et al., 2005). These types of distorted thinking may 
be manifested through the establishment of unrealistic eating and weight loss goals, self-
criticism in response to overeating or gaining weight, and/or hopelessness about 
controlling weight (Wadden, Crerand, et al., 2005). Such cognitions, all of which impair 
the ability to induce and/or maintain weight loss, are identified and modified during the 
course of behavior therapy.  
The subjects who received behavior therapy during the original trial (Wadden, 
Berkowitz, et al., 2005) followed versions of a manualized, behavioral weight loss 
program (i.e., Brownell, 1998; Brownell & Rodin, 1990; Brownell & Wadden, 1999). 
Components of this program included (a) self-monitoring food intake and physical 
activity behaviors, (b) addressing and establishing realistic weight loss goals, (c) 
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modifying eating behaviors (e.g., portion sizes, times of eating, speed of eating), (d) 
controlling the external environment involving food (i.e., stimulus control), (e) increasing 
programmed activity and lifestyle activity, and (f) modifying maladaptive cognitions 
related to weight control. The functions of these behavioral interventions are discussed in 
Chapter Two.  
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Chapter Two: Literature Review 
Definition of Obesity 
Obesity is defined as an excess of adipose tissue that results from a consistently 
greater energy intake than expenditure (Grilo, 2006). It commonly is measured by 
calculating the body mass index (BMI), which is computed by dividing weight in 
kilograms by height in meters squared (kg/m
2
) (Field et al., 2002; Foster & Kendall, 
1994). The NHLBI (1998) recommends using BMI to assess obesity because it generally 
correlates well with amount of adipose tissue. In addition, BMI accounts for one’s height, 
a critical factor that is not directly considered when assessing weight with pounds or 
kilograms, and therefore serves as a better predictor of body fatness. Epidemiological 
studies often use BMI to assess the relationship between weight and morbidity, and 
current public health recommendations related to weight status are based on BMI.  
According to the NHLBI (1998), persons with a BMI of 18.5 to 24.9 kg/m
2 
are 
considered to have a healthy weight. Individuals with a BMI below 18.5 kg/m
2
 are 
classified as underweight, whereas those with a value of 25.0 to 29.9 kg/m
2 
are classified 
as overweight. Overweight status, defined as weighing more than a standard level for age 
and height, confers a heightened risk of morbidity (NHLBI, 1998). Persons with a BMI 
equal to or greater than 30.0 kg/m
2
 are considered to have excessive body fat and, thus, 
are classified as obese. Obesity is subdivided into three classes, which are determined by 
BMI and relate to disease risk (NHLBI, 1998). Class I obesity represents mild obesity 
(30.0 – 34.9 kg/m2), Class II obesity represents moderate obesity (35.0 – 39.9 kg/m2), and 
Class III obesity represents severe/extreme obesity (≥ 40 kg/m2). The risk of obesity-
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related morbidity and mortality increases linearly with BMI (Fabricatore & Wadden, 
2006).    
 While BMI is considered a valuable tool in assessing overall disease risk, the risk 
of adverse health outcomes associated with BMI, including mortality, varies with age, 
sex, race/ethnicity, and socioeconomic status (Havas, Aronne, & Woodworth, 2009). This 
variation may reflect population-specific differences in body composition, fat 
distribution, and genetic susceptibility. Because height affects BMI nonlinearly, BMI also 
may provide an inaccurate measure of adipose tissue in very tall or very short people 
(Rothman, 2008). In addition, BMI may overestimate obesity in muscular persons and 
may underestimate obesity in elderly persons (Grilo, 2006). Clinical judgment and the 
use of other assessment tools, including waist circumference and waist-to-hip ratio, are 
available to help clinicians develop a more complete picture of the health risks associated 
with obesity. Additional factors to consider when assessing these risks include patients’ 
global health, family histories, and current lifestyles (Havas et al., 2009). 
 
Prevalence of Obesity 
 The prevalence of obesity is growing at a rapid pace in the United States. Data 
from the National Health Examination Survey (NHES) and the National Health and 
Nutrition Examination Survey (NHANES) demonstrate a steady rise in obesity rates over 
the second half of the 20
th
 century (Ogden et al., 2006). Obesity in the United States 
increased in prevalence from 13.4% in 1960 to 30.9% in 2000 (Flegal, Carroll, Ogden, & 
Johnson, 2002). Similar increases were observed in men and women across all age 
groups and across all racial/ethnic populations during this span (Flegal et al., 2002; 
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Hedley et al., 2004). Although the prevalence of obesity is higher in women than men, 
recent statistics suggest that obesity rates are stabilizing (but not declining) among 
women while continuing to climb among men (Ogden et al., 2006). It is estimated that 
34.1% of adults, ages 20 years and older, currently are overweight and that 32.2% are 
obese (Ogden et al., 2006). An estimated 4.8% of the adult population is extremely obese 
(BMI ≥ 40 kg/m2).  
The rate of overweight children and adolescents in the United States also has risen 
dramatically. Overweight prevalence among these populations, on average, has tripled 
since the mid-1970s (Centers for Disease Control and Prevention, 2006a). In 2003-2004, 
13.9% of children, ages 2 to 5 years, were overweight (BMI ≥ sex-specific 95th 
percentile), compared to 5% of same-aged peers in 1976-1980. An estimated 18.8% of 6- 
to 12-year-olds and 17.4% of 12- to 19-year-olds were overweight in 2003-2004, 
compared to 6.5% and 5% of these populations in 1976-1980. These statistics are 
alarming, given reports that obesity that develops in childhood is associated with severe 
obesity in adulthood (Whitaker, Wright, Pepe, Seidel, & Dietz, 1997).  
In the United States, the prevalence of obesity in most racial/ethnic populations is 
higher than in the non-Hispanic White population. In 2003-2004, 45% of non-Hispanic 
Black adults and 36.8% of Mexican-American adults were classified as obese, compared 
to 30.6% of non-Hispanic White adults (Ogden et al., 2006). The prevalence of children 
and adolescents who were overweight, or at-risk for overweight, also was higher in non-
Hispanic Black and Mexican-American populations than in the non-Hispanic White 
population (Ogden et al., 2006). The effects on weight of certain genetic and cultural 
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factors associated with different racial/ethnic groups may account for these differences in 
prevalence (Kumanyika, 2002). In addition, persons of lower socioeconomic status are 
found to display higher rates of obesity than those of higher socioeconomic status, owing, 
in part, to the greater consumption of inexpensive, energy-dense foods by members of 
impoverished populations (Drewnowski & Specter, 2004). The inverse relationship 
between income and obesity in the United States, however, appears to be weakening, and 
recent trends suggest that persons of any socioeconomic status are becoming increasingly 
susceptible to weight gain (Zhang & Wang, 2004). 
Etiology of Obesity 
Genetic Factors 
The contributions of genetics to weight status have been established through 
studies of family relationships, parents and offspring, and twins and adopted children 
(Farooqi & O’Rahilly, 2006; Marti, Moreno-Aliaga, Hebebrand, & Martinez, 2004). 
These investigations show that genetics play a significant role in the development of 
obesity. It is estimated that 40 to 70% of the variation in BMI is heritable (Farooqi & 
O’Rahilly, 2006; Marti et al., 2004). Although certain cases may be explained by 
monogenic mutations, obesity is considered primarily a polygenic condition (Farooqi & 
O’Rahilly, 2006; Marti et al., 2004). Based on the latest update of the human obesity 
gene map (Rankinen et al., 2006), 127 different candidate genes have been associated 
with obesity. Genetic predisposition is widely assumed to affect both energy intake and 
energy expenditure (Marti et al., 2004).  
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A variety of genetic products, such as cholesystokin (CCK), peptide YY (PYY3-
36), and glucagon-like peptide (GLP-1), has been shown to affect energy balance (Korner, 
Woods, & Woodworth, 2009). Two peptides – leptin and ghrelin – have gained particular 
attention with respect to their homeostatic effects (Klok, Jakobsdottir, & Drent, 2007; 
Korner et al., 2009). Leptin is a protein that is produced and released into the circulatory 
system by the body’s adipose tissue. It primarily serves as a feedback mechanism that 
inhibits appetite and decreases food intake via interactions with neurons in the 
hypothalamus. Interestingly, obese persons tend to have high circulating levels of leptin 
(Klok et al., 2007; Korner et al., 2009). Leptin injections do little to induce weight loss in 
these individuals. Thus, researchers have surmised that obese persons likely are resistant 
to the effects of leptin (Klok et al., 2007; Korner et al., 2009).  
Ghrelin is a 28–amino acid peptide that is synthesized mainly in the stomach and 
small intestines before meals and during periods of food deprivation (Klok et al., 2007; 
Korner et al., 2009). The effects of ghrelin on energy balance are essentially opposite to 
those of leptin. Ghrelin operates through the hypothalamus to attenuate the effects of 
leptin and to increase hunger and food intake (Klok et al., 2007; Korner et al., 2009). 
Obese persons do not lose sensitivity to ghrelin; in fact, they may be oversensitive to it. 
Circulating levels of ghrelin tend to increase as obese persons lose weight, a reaction that 
represents a physiological adaptation to the positive energy balance associated with 
obesity (Klok et al., 2007; Korner et al., 2009). Thus, ghrelin appears to contribute to the 
long-term regulation of body weight by adapting its secretions to changes in weight 
(Klok et al., 2007; Korner et al., 2009).  
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Genetic predisposition also appears to contribute to obesity by affecting energy 
expenditure (Marti et al., 2004). The amount of energy expended per day is the product of 
three factors: (a) resting metabolic rate (i.e., energy expended when resting in a fasting 
state under ambient conditions), (b) physical activity (i.e., energy expended through 
spontaneous and voluntary physical activity), and (c) thermic effect of food (i.e., energy 
expended when digesting and absorbing food). Approximately 50 to 70% of daily energy 
expenditure is attributable to resting metabolic rate; 20 to 40% to physical activity; and 
10% to the thermic effect of food (Tataranni & Ravussin, 2002). Genetic differences 
across these variables have been shown to affect weight (Bouchard, 2007; Foster, 
Wadden, & Vogt, 1997b; Tataranni & Ravussin, 2002; Zurlo, Larson, Bogardus, & 
Ravussin, 1990).  
Environmental Factors 
The obesity epidemic is considered largely the product of a toxic environment that 
surrounds Americans with inexpensive, high-calorie foods (Horgen & Brownell, 2002). 
The dramatic rise in obesity rates is evidence that environmental factors, in addition to 
genetic determinants, independently affect energy balance (Marti et al., 2004). Highly 
palatable, energy-dense foods in large portion sizes have become readily available in 
most regions of the United States (Young & Nestle, 2002). The number of fast-food 
restaurants offering tremendous portions of fatty foods has more than doubled since the 
mid-1970s (Austin et al., 2005; Chou, Grossman, & Saffer, 2004). Convenience stores 
are stocked continually with ever-increasing portions of sugary snacks (Booth, Pinkston, 
& Poston, 2005). Not surprisingly, obesity rates have risen in parallel with these changes 
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in the food environment (Astrup, 2005; Nielsen & Popkin, 2003), and recent statistics 
confirm that Americans are consuming more calories now than in previous decades (Kant 
& Graubard, 2006). Between 1971 and 2002, the number of calories consumed by 
Americans increased by an estimated 12% (Kant & Graubard, 2006).  
Several studies have demonstrated that larger portion sizes are associated with 
greater energy intakes (Diliberti, Bordi, Conklin, Roe, & Rolls, 2004; Rolls, Morris, & 
Roe, 2002; Wansink & Cheney, 2005; Wansink & Kim, 2005). Diliberti et al. (2004) 
reported that diners who purchased larger portions of a pasta entrée increased their total 
consumption of the entrée by 43% and of the entire meal by 25%, compared with those 
who purchased standard portions of a pasta entrée. Wansink and Kim (2005) found that 
persons who were given a large container of popcorn consumed 45.3% more popcorn 
than those who were given a medium container of popcorn. Even when the popcorn was 
stale, subjects consumed 33.6% more popcorn when it was from a large container. 
Similarly, Wansink and Cheney (2005) observed that persons who served themselves 
from large serving bowls at a Super Bowl party consumed 56% more food than those 
who served themselves from medium serving bowls. These studies clearly demonstrate 
that being offered or served large portion sizes is associated with excessive eating.  
The greater availability and consumption of sugar-based drinks also has 
contributed to increased obesity rates across the nation. From 1977 to 2001, the amount 
of energy consumed from sweetened beverages increased by 135%, which translated to 
the consumption of an additional 278 kilocalories per day (kcal/day) (Karppanen & 
Mervaala, 2006). The greater consumption of sugar-based drinks may be explained by 
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increases in sodium intake, and subsequent levels of thirst, experienced by Americans in 
recent decades (Karppanen & Mervaala, 2006). The impact of sugar-based drinks on 
childhood obesity is particularly concerning. In school-aged children, the incidence of 
obesity is 1.6 times greater with each serving of sweetened drinks consumed per day 
(Ludwig, Peterson, & Gortmaker, 2001). Unfortunately, a number of public schools 
continue to house soft-drink vending machines in their cafeterias (Johnston, Delva, & 
O’Malley, 2007). 
The obesity epidemic also has been influenced by a shift in the percentages of 
meals prepared at home to meals eaten outside of home (Wolf & Woodworth, 2009). A 
greater frequency of consuming meals at fast-food restaurants, in particular, has 
paralleled the weight gain observed among Americans (Astrup, 2005; Nielsen & Popkin, 
2003). In a 15-year prospective analysis, Pereira et al. (2005) found that subjects who ate 
meals at fast-food restaurants more than twice weekly gained an extra 4.5 kg and had a 
two-fold greater increase in insulin resistance than those who ate less than one meal per 
week at these restaurants. In addition, McCrory et al. (1999) found that the frequency of 
eating foods at restaurants that served high-fat options, such as fried chicken, fried fish, 
burgers, pizza, Chinese food, and Mexican food, was directly associated with body 
fatness, along with higher levels of total fat and saturated fat intake and a lower level of 
fiber intake. Eating outside of the home, therefore, appears to increase the risk of 
consuming large portions of unhealthy, energy-dense foods. 
Reductions in energy expenditure have accompanied increases in energy intake 
among Americans (Blair & Church, 2004). With advancements in technology, such as 
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motorized transport and labor-saving devices, Americans defaulted to increasing amounts 
of sedentary behavior over the second half of the 20
th
 century (Dzewaltowski, 2008). 
Currently less than 30% of Americans are physically active on a regular basis (Kruger, 
Yore, & Kohl, 2007), despite indications that persons who are physically active are 
significantly less likely to be obese, to become obese, and to experience obesity-related 
health consequences (Grilo, 2006). Unfortunately, the trend towards physical inactivity 
appears to begin in childhood, as less than 10% of public schools provide physical-
activity classes on a daily basis (Centers for Disease Control and Prevention, 2006b). The 
lack of physical activity offered in schools, combined with evidence that children are 
direct targets of marketing by food companies (Story & French, 2004), provides an 
environment ripe for the development of obesity in youth. To combat childhood obesity, 
the CDC recently has recommended that schools allot additional time for physical 
activity, integrate nutritional education with physical activity, include noncompetitive 
sports (e.g., dance) in physical-education curricula, and educate students on the effects of 
sedentary behavior on health (Katz et al., 2005).  
Psychological Factors 
The psychological causes of obesity are less understood than the physiological 
and environmental determinants. Research primarily has focused on the association 
between obesity and depression (Simon et al., 2006). Depression, in its typical form, is 
associated with weight loss, whereas weight gain is characteristic of atypical depression 
(American Psychiatric Association, 2000). Weight gain that accompanies depression may 
be attributable to a variety of factors, including increased appetite, reduced physical 
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activity, increased binge eating, and the side effects of antidepressant medications (Simon 
et al., 2006). While the presence of depression has been found to predict obesity (Blaine, 
2008; Hasler et al., 2004), the presence of obesity also has been found to predict 
depression (Roberts, Deleger, Strawbridge, & Kaplan, 2003). Thus, there appears to be a 
complex bi-directional relationship between depression and weight, such that obesity 
may be either a cause or a consequence of depressed mood (Stunkard, Fernstrom, Price, 
Frank, & Kupfer, 1990). A variety of behavioral, cognitive, physiological, and social 
mechanisms may be responsible for these causal pathways (Markowitz, Friedman, & 
Arent, 2008).  
Obesity-Related Comorbidities 
Medical Comorbidities 
Obesity can have detrimental effects on almost every major organ system in the 
human body and increases the risk of a variety of medical conditions, potentially leading 
to early mortality (Bray, 2004; Brown et al., 2009; Field et al., 2002). In an alarming 
analysis (Olshansky et al., 2005), the gains in life expectancy achieved in the United 
States during the 20
th
 century are projected to decline as a result of the adverse health 
consequences of obesity. There is a strong relationship between weight gain and 
premature death, with cardiovascular disease representing the principal cause of death 
among obese patients (Van Gaal, Mertens, & De Block, 2006). Obesity increases the risk 
of developing a variety of cardiovascular risk factors, including hypertension, 
hypercholesterolemia, and type 2 diabetes (Wilson, D’Agostino, Sullivan, Parise, & 
Kannel, 2002). The risk of developing various cancers (e.g., esophageal, colorectal, 
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gallbladder, breast, uterine) increases with excess weight, and BMI correlates 
significantly with death from all cancers (Calle, Rodriguez, Walker-Thurmond, & Thun, 
2003). Obesity is associated with pulmonary diseases and musculoskeletal problems, 
such as obstructive sleep apnea and osteoarthritis (Coughlin, Mawdsley, Mugarza, 
Calverley, & Wilding, 2004; Wearing, Hennig, Byrne, Steele, & Hills, 2006). Finally, 
obesity predisposes patients to complications with gastrointestinal and hepatic 
functioning (e.g., gallbladder disease), reproductive functioning (e.g., polycystic ovary 
syndrome, erectile dysfunction), and dermatologic functioning (e.g., acanthosis nigricans) 
(Bray, 2004; Brown et al., 2009; Field et al., 2002).  
Obesity also is associated with the metabolic syndrome, a cluster of 
cardiometabolic factors that increases the risk of heart attack, stroke, and type 2 diabetes 
(Despres & Lemieux, 2006). These risk factors, as defined by the National Cholesterol 
Education Program Adult Treatment Panel III (NCEP ATP III), include elevated waist 
circumference (men = > 102 cm, women = > 88 cm); elevated blood pressure (≥ 130/≥ 85 
mmHg); elevated triglyceride concentrations (≥ 150 mg/dL); high fasting glucose 
concentrations (≥ 110 mg/dL), and low high-density lipoprotein (HDL) cholesterol levels 
(men = < 40 mg/dL, women = < 50 mg/dL). The metabolic syndrome is associated with 
increased risks of cardiovascular mortality and all-cause mortality (Hunt, Resendez, 
Williams, Haffner, & Stern, 2004).  
With the rapid rise in childhood and adolescent obesity in the United States, 
obesity-related comorbidities, many of which were previously observed primarily in 
adults, are becoming increasingly common in younger populations (Dietz & Robinson, 
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2005). The incidences of sleep apnea and gallbladder disease in children and adolescents 
tripled between the late 1970s and late 1990s. Type 2 diabetes now accounts for as many 
as 45% of all newly diagnosed cases of diabetes in pediatric populations. The risk factors 
associated with cardiovascular disease, such as elevated blood pressure and dyslipidemia, 
also are increasing in children (Dietz & Robinson, 2005). Fortunately, the significance of 
obesity prevention in children has been recognized by several public health organizations 
in recent years, including the Robert Wood Johnson Foundation, which has vowed to 
devote $500 million in funds to combat childhood obesity and to reverse the obesity 
epidemic in American children by 2015 (Havas et al., 2009).  
Psychosocial Comorbidities 
Several psychosocial complications are related to obesity. Obese individuals 
experience an abundance of prejudice and discrimination across many domains of living 
(Sarlio-Lahteenkorva, 2001; Wadden et al., 2002; Wang et al., 2004). Negative attitudes 
toward obese persons have been documented across education, employment, and social 
settings (Grilo, 2006). In the workplace, for example, obese persons face discrimination 
in several areas, including selection, placement, compensation, and promotion (Roehling, 
1999). Such bias appears to be especially pronounced for overweight women (Pingitore, 
Dugoni, Tindale, & Spring, 1994). Gortmaker, Must, Perrin, Sobol, and Dietz (1993) 
found that women who were overweight completed fewer months of school, were less 
likely to be married, and had lower household incomes than nonoverweight women, 
despite displaying comparable intellectual aptitudes. Overweight children and 
adolescents are not immune to the effects of prejudice and discrimination, as they tend to 
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have fewer friends, to be excluded from games and sports, and to be teased more often 
than their nonoverweight peers (Pierce & Wardle, 1997). It has long been known that 
children as young as 10 years of age display negative bias toward their overweight peers 
(Richardson, Goodman, Hastorf, & Dornbusch, 1961), a finding that was replicated more 
recently by Latner and Stunkard (2003). Prejudice towards the obese population is so 
prevalent that even some health care professionals have been found to endorse negative 
attitudes toward obese patients, viewing them as overindulgent, lazy, and noncompliant 
(Foster et al., 2003; Teachman & Brownell, 2001).  
Obese patients who seek professional assistance with weight loss tend to 
experience significant psychopathology (Fitzgibbon et al., 1993; Wadden et al., 2002). 
Binge-eating disorder (BED) has been found to affect 10 to 15% of patients who seek 
weight loss treatment (Stunkard, 2002), as compared with 1.2% of the general population 
(prevalence rates vary based on measurement criteria) (Hudson, Hiripi, Pope, & Kessler, 
2007). BED currently is proposed as a diagnosis requiring further study in the Diagnostic 
and Statistical Manual of Mental Disorders, 4
th
 Edition, Text Revision (DSM-IV-TR) 
(American Psychiatric Association, 2000). BED is characterized by episodes of eating, in 
a discrete period of time, an amount of food that is objectively larger than most people 
would eat under similar conditions. These episodes are accompanied by a sense of loss of 
control of eating. Indicators of loss of control include eating very rapidly, eating until 
uncomfortably full, eating when not physically hungry, eating alone out of 
embarrassment, and feeling disgusted or guilty after overeating. BED is differentiated 
from bulimia nervosa by the absence of inappropriate compensatory behaviors, such as 
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purging, fasting, or excessive exercise. Compared to those without BED, obese patients 
with BED display more symptoms of depression and borderline personality disorder, 
along with a significantly greater lifetime prevalence of any Axis I disorder, including 
substance abuse or dependence (de Zwaan, 2001; Wadden et al., 2002).  
 Night-eating syndrome (NES) is another condition found among obese patients in 
clinical settings. The prevalence of NES ranges from 1.5 to 6% in the general population 
and from 6 to 16% in obese patients who seek weight loss treatment (Stunkard et al., 
2009). NES is not currently defined as an eating disorder in the DSM-IV-TR (2000), 
although recognition of its principal characteristics has increased over the past decade. 
First identified by Stunkard and colleagues in 1955 (Stunkard, Grace, & Wolff, 1955), 
NES is defined by two core diagnostic criteria: (a) evening hyperphagia, defined as the 
consumption of at least 25% of daily food intake after the evening meal, and/or (b) 
presence of nocturnal awakenings with ingestions of food several times per week 
(Stunkard et al., 2009). Patients with NES experience a shift in the normal circadian 
rhythm of food consumption toward later in the day and, thus, experience a delay of 
appetite in the morning, overconsumption of food at night, and sleep onset and sleep 
maintenance insomnia. In addition, patients with NES experience more psychiatric 
comorbidity than patients without NES, including depressed mood, low self-esteem, and 
substance-use disorders (Stunkard et al., 2009).   
Depression represents another condition found among those who seek treatment 
for weight loss, affecting approximately 10% of obese patients in clinical settings 
(Wadden et al., 2000). As previously described, the relationship between obesity and 
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depression is complex. Depressed mood is positively correlated with BMI (de Zwaan, 
2001; Wadden et al., 2002) and may be either a cause or a consequence of obesity 
(Stunkard et al., 1990). Depression is very common among extremely obese patients, 
such as those who present for bariatric surgery (Wadden, Sarwer, et al., 2007). Persons 
with a BMI of 40 kg/m
2
 or greater are approximately 5 times more likely to have 
experienced a major depressive episode than those of average weight (Onyike, Crum, 
Lee, Lyketsos, & Eaton, 2003). In addition, the risk of attempted suicide increases as 
BMI exceeds 40 kg/m
2
 (Dong, Li, Li, & Price, 2006). Dong et al. (2006) found that 
compared to the general population, the risk of attempted suicide is 87% higher for 
persons with a BMI of 40 to 50 kg/m
2
 and 122% higher for those with a BMI greater than 
50 kg/m
2
. The adverse psychological reactions of extremely obese persons may be 
attributable to their severe impairment in health-related quality of life, as well as to their 
heightened exposure to prejudice and discrimination (Fabricatore, Wadden, Sarwer, & 
Faith, 2005; Wadden et al., 2002).  
 Finally, obesity is associated with body image dissatisfaction, which is widely 
considered a function of Western society’s pervasive emphasis on thinness as the ideal 
(Grilo, 2006). Although the degree of disturbance varies across different subgroups of the 
population (Kumanyika, Wilson, & Guilford-Davenport, 1993), the prevalence of body 
image dissatisfaction has increased dramatically in men and women since the 1970s 
(Sarwer & Thompson, 2002). Body image dissatisfaction has become so common that it 
has been termed a “normative discontent” (Rodin, Silberstein, & Striegel-Moore, 1985). 
There appears to be a relationship between body image dissatisfaction and increased 
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psychological distress, including low self-esteem and depressive symptoms (Foster, 
Wadden, & Vogt, 1997a). A minority of obese patients who seek weight loss treatment 
are likely to suffer from clinically significant depression as a result of their body image 
concerns (Sarwer, Wadden, & Foster, 1998; Wadden et al., 2002). In addition, patients 
who endorse a negative body image may have difficulty controlling their weight in the 
long term (Cooper & Fairburn, 2002). Interestingly, the severity of obesity does not 
appear to influence the severity of body image dissatisfaction or the relationship between 
body image dissatisfaction and psychological symptoms (Sarwer et al., 1998).  
Treatment Approaches 
 There are three general approaches to the management of obesity. The first 
approach is behavior therapy, also known as behavioral weight control or lifestyle 
modification. Behavior therapy is considered the first-line approach to obesity (NHLBI, 
2000; Phelan & Wadden, 2002). It consists of diet, physical activity, and behavior 
modification (Foster et al., 2005; Wadden, Crerand, et al., 2005). Pharmacotherapy 
represents another approach to obesity. The use of medications is indicated for patients 
with a BMI equal to or greater than 30 kg/m
2
, or for those with a BMI of 27 to 29.9 kg/m
2
 
who exhibit obesity-related medical comorbidities (NHLBI, 2000). The third approach to 
obesity is surgical intervention. Weight loss surgery is reserved for patients with a BMI 
equal to or greater than 40 kg/m
2
, or with a BMI of 35 to 39.9 kg/m
2
 in the presence of 
comorbid conditions (NHLBI, 2000). 
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Behavior Therapy 
Behavior therapy is considered the cornerstone of treatment for obesity (Foster et 
al., 2005; Wadden, Crerand, et al., 2005). The goal of behavior therapy is to modify 
patients’ eating and physical activity behavior in order to achieve clinically significant 
weight loss and health improvements. Behavior therapy consistently has been shown to 
produce these favorable outcomes (Foster, 2006; Wadden, Crerand, et al., 2005; Wing, 
2002). 
Originating from learning theory in the late 1960s, behavior therapy assumes that 
eating and physical activity behavior are learned phenomena that are amenable to 
behavior modification through the application of behavioral principles and techniques 
(Foster et al., 2005; Wadden, Crerand, et al., 2005). Classical conditioning and operant 
conditioning, therefore, serve important functions in treatment (Foster et al., 2005; 
Wadden, Crerand, et al., 2005), as previously described. Identifying and modifying the 
conditions that maintain unhealthy eating and exercise behavior are central goals in 
therapy (Foster et al., 2005; Wadden, Crerand, et al., 2005).  
Treatment typically is delivered to closed groups of 10 to 20 patients on a weekly 
basis for 16 to 26 weeks, followed by monthly or every-other-month maintenance 
sessions (Foster et al., 2005; Wadden, Crerand, et al., 2005). Sessions usually last from 
60 to 90 minutes. This approach allows time for patients to achieve a 10% loss of initial 
weight during the course of treatment, which is considered a clinically significant weight 
loss (NHLBI, 1998). Renjilian et al. (2001) found that group therapy induced larger 
initial losses (approximately 2 kg) than individual therapy, even among patients who 
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preferred individual treatment but were randomly assigned to receive group care. Group 
therapy allows patients to receive mutual support and to engage in healthy competition 
with each other, which may account for the greater losses achieved with this modality. In 
addition, group therapy is more cost-effective than individual therapy (Wadden, Crerand, 
et al., 2005).  
Behavior weight loss interventionists consist of behavioral psychologists, 
registered dietitians, exercise specialists, and other health-related professionals (Wadden, 
Crerand, et al., 2005; Wadden & Osei, 2002). Patients are expected to assume an active 
role in treatment and, thus, are prescribed homework assignments on a regular basis. 
These assignments are tailored toward modifying their eating, physical activity, and 
thinking habits. Group sessions principally are devoted to reviewing their homework 
assignments and problem solving their difficulties with implementing behavioral 
changes. A different educational topic related to healthful behaviors is presented by the 
group leader at each session, and patients are encouraged to integrate this information 
into their weight control efforts. Patients are weighed at each session as a measure of 
their adherence to and progress in treatment (Wadden, Crerand, et al., 2005; Wadden & 
Osei, 2002).  
There are several key components of behavior therapy. Recording food intake and 
physical activity through the use of detailed, self-monitoring forms is perhaps the most 
important aspect of treatment (Wadden, Crerand, et al., 2005). Studies consistently 
demonstrate an association between recording food intake and improved weight control 
(Berkowitz, Wadden, Tershakovec, & Cronquist, 2003; Head & Brookhart, 1997; 
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Wadden, Crerand, et al., 2005). Obese patients tend to underestimate their food intake by 
approximately 40 to 50% per day, which is attributable to their difficulty in estimating 
portion sizes, macronutrient compositions, and calorie contents of food (Lichtman, 
Pisarka, & Berman, 1992). Keeping food records reduces (but not eliminates) their 
tendency to underestimate energy intake and, thus, improves their ability to lose weight 
(Wadden, Crerand, et al., 2005). Patients initially are instructed to record the types, 
amounts, and calorie values of food consumed per day. As therapy progresses, they are 
asked to include the times, places, and emotions associated with their eating in order to 
elucidate patterns that may be contributing to their obesity, as well as to identify strategic 
points of intervention for the therapist. Self-monitoring often reveals behaviors of which 
patients were previously unaware (e.g., grazing on sugary snacks), which consequently 
helps them focus their efforts on modifying these behaviors (Wadden, Crerand, et al., 
2005).  
 Dietary change represents another component of behavior therapy (Wadden & 
Osei, 2002; Wing, 2002). The NHLBI (1998) recommends that overweight and obese 
patients follow a portion-controlled, low-calorie diet and reduce their calorie intake by 
approximately 500 kcal/day. This guideline generally translates to the consumption of 
1,000 to 1,500 kcal/day for obese women and 1,500 to 1,800 kcal/day for obese men, 
although patients’ exact calorie goals are based on their baseline energy requirements 
(Wadden & Osei, 2002). Patients also are expected to limit their fat intake to no greater 
than 30% of total kcal/day. Additional dietary prescriptions are based on the latest dietary 
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guidelines by the Department of Health and Human Services (HHS) and the Department 
of Agriculture (USDA) (e.g., 2005 Dietary Guidelines for Americans). 
Diets that prescribe fewer than 800 kcal/day, known as very-low-calorie diets 
(VLCDs), have been shown to induce weight loss that is nearly double the size of that 
achieved with conventional diets consisting of 1,200 to 1,500 kcal/day (Tsai & Wadden, 
2006). However, patients who are prescribed VLCDs usually regain 35 to 50% of their 
weight within the first 2 years following treatment. As a result, few statistically 
significant differences in weight losses have been detected at follow-up between patients 
treated with VLCDs and those treated with more balanced-deficit diets (1,000 to 1,500 
kcal/day) (Wadden & Osei, 2002). Patients prescribed VLCDs also require careful 
medical supervision, particularly in monitoring the development of gallstones, and incur 
high expenses owing to the cost of ongoing medical care. Thus, VLCDs do not appear to 
offer any significant advantages over more balanced-deficit diets in the long term 
(Wadden & Osei, 2002).  
A variety of dietary strategies may be used in behavior therapy. No single 
approach works for every patient because of the diverse needs of obese individuals 
(Aronne, 2002; Kumanyika, 2002). Examples of dietary options include meal 
replacement products (i.e., prepackaged meals, shakes, and snack bars) and structured 
meal plans. The use of meal replacement products, in conjunction with low-fat, low-
calorie diets, has been shown to facilitate the induction and maintenance of weight loss in 
short- and long-term trials (Ditschuneit, Flechtner-Mors, Johnson, & Adler, 1999; 
Flechtner-Mors, Ditschuneit, Johnson, Suchard, & Adler, 2000). Replacing one or two 
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meals per day with meal replacement products also has been found to produce greater 
weight loss than isocaloric diets composed of conventional foods (Heymsfield, van 
Mierlo, van der Knapp, Heo, & Frier, 2003). The benefits of these products derive from 
their fixed quantity and calorie content, which facilitate dietary adherence. Replacing 
conventional meals and snacks with calorie-specific products removes the error, and 
subsequent weight gain, associated with underestimating calorie intake. In addition, these 
products simplify food choices, require minimal preparation, and prevent exposure to 
unhealthy foods, all of which facilitate weight control (Tsai & Wadden, 2006).  
Structured meal plans, also known as portion-controlled servings of conventional 
foods, offer an alternative to meal replacement products. This approach consists of 
providing patients with calorie-specific menus, recipes that use conventional food, and 
grocery lists, thereby exposing patients to models of healthful eating (Fabricatore & 
Wadden, 2006). The goal of this approach is to impose greater structure on patients’ 
eating behaviors in order to improve their dietary adherence. Studies show that the use of 
structured meal plans, like meal replacement products, produces greater weight loss than 
isocaloric, self-selected diets (Jeffery et al., 1993; Wing et al., 1996). 
 Although patients in behavior therapy are traditionally prescribed a low-fat diet, 
debate currently exists over whether low-carbohydrate diets lead to greater weight loss 
than low-fat diets. Low-carbohydrate diets, such as the Atkins diet (Atkins, 1998), 
promote a state of ketosis by allowing for the unlimited consumption of protein and fat at 
the expense of carbohydrates. Despite the unlimited amount of protein and fat intake 
allowed, dieters appear to reduce their overall calorie intake, which may be attributable to 
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increased satiation (from high protein intake) and/or decreased dietary variability (Makris 
& Foster, 2005). Studies comparing the efficacy of low-carbohydrate diets and low-fat 
diets show greater weight loss at 6 months with low-carbohydrate diets but no differences 
in weight loss at 12 months (Nordmann et al., 2006). Two recent studies, however, have 
demonstrated greater loss with low-carbohydrate diets at 12 months (Gardner et al., 2007; 
Shai et al., 2008). The safety concerns associated with consuming large amounts of 
saturated fat, including elevations in low-density lipoprotein (LDL) cholesterol and risk 
of cardiovascular disease, must be weighed against the potential benefits of following a 
low-carbohydrate diet (Astrup, Larsen, & Harper, 2004).  
Another component of behavior therapy includes establishing realistic weight loss 
goals with patients, along with increasing their appreciation of achieving a modest loss. A 
loss of 5 to 10% of initial weight can substantially decrease the risk of obesity-related 
diseases and improve the health outcomes of obese patients (Foster, 2006; Wadden, 
Crerand, et al., 2005; Wing, 2002). Research shows that patients generally achieve losses 
of 8 to 10% of initial weight during the first 6 months of treatment, well within the 
parameters of a clinically significant outcome (NHLBI, 1998). The health benefits of 
modest loss were clearly demonstrated in a landmark trial by the Diabetes Prevention 
Program (DPP) Research Group (Knowler et al., 2002). Over a mean follow-up period of 
2.8 years, the DPP found that an intensive lifestyle intervention program (behavior 
therapy), designed to induce a loss of 7% of initial weight, successfully reduced the 
incidence of type 2 diabetes by 58% in overweight subjects with impaired glucose 
tolerance compared with a placebo group (Knowler et al., 2002). In addition, behavior 
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therapy was significantly more effective than metformin therapy in reducing diabetic risk 
among subjects. A follow-up study currently is being conducted by the National Institutes 
of Health (NIH) to determine the long-term effects of lifestyle modification on morbidity 
and mortality in overweight and obese individuals who already have developed type 2 
diabetes (Ryan et al., 2003).  
Maladaptive cognitions related to weight control are also addressed in behavior 
therapy. As described previously, cognitions that commonly undermine efforts to lose 
weight tend to be dichotomous, catastrophic, and overgeneralized (Brownell, 2004; 
Wadden, Crerand, et al., 2005). These types of distorted thinking may be manifested 
through the establishment of unrealistic eating and weight loss goals, self-criticism in 
response to overeating or gaining weight, and/or hopelessness about controlling weight 
(Wadden, Crerand, et al., 2005). For example, despite the demonstrated benefits of 
modest weight loss, many obese patients unrealistically desire a loss of over 25% of 
initial weight and, thus, may have difficulty accepting a loss that falls below this 
expectation (Foster et al., 2005; Wadden, Berkowitz, Sarwer, Prus-Wisniewski, & 
Steinberg, 2001). Others may display marked body image concerns that disrupt their 
ability to appreciate their weight loss (Cooper & Fairburn, 2002). Cognitive 
interventions, such as self-monitoring negative thoughts and role playing rational 
responses, are used in behavior therapy to restructure dysfunctional thoughts about losing 
weight (Brownell, 2004). Interestingly, owing to the large body of evidence in support of 
behavior therapy, randomized controlled trials examining the efficacy of cognitive 
approaches to obesity currently are lacking (Fabricatore, 2007). Although cognitive 
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therapy is purported to improve long-term weight control (Cooper & Fairburn, 2002), 
empirical trials are needed to determine the comparative effectiveness of behavior 
therapy and cognitive therapy in the treatment of obesity.   
A large portion of behavior therapy is devoted to modifying patients’ eating 
behavior (Brownell, 2004; Wadden, Crerand, et al., 2005). Maladaptive eating habits 
have been shown to contribute significantly to weight gain. Eating infrequent meals and 
at later times in the day, for example, are associated with obesity (Taylor, Missik, Hurley, 
Hudak, & Logue, 2004). Accordingly, patients are provided instruction on ways to 
improve their eating behavior. They are taught to control their portion sizes (e.g., 
weighing and measuring food), to decrease their speed of eating (to improve recognition 
of fullness), and to eat at regular time intervals (to improve appetite control). In addition, 
they are taught to avoid other activities while eating, as well as to limit their eating to 
certain rooms in the home (e.g. kitchen, dining room), in order to prevent and/or 
extinguish any associations between eating and non-eating-related stimuli (Brownell, 
2004).  
The principle of stimulus control is applied throughout the course of therapy 
(Brownell, 2004; Wadden, Crerand, et al., 2005). In the context of obesity treatment, 
stimulus control refers to the act of controlling the external environment involving food. 
Patients are encouraged to avoid high-risk venues (e.g., fast-food restaurants, 
convenience stores, buffets); avoid aisles in grocery stores that contain energy-dense 
snacks; store high-fat, high-sugar foods out of sight; shop from a food list; keep serving 
dishes off the table; and serve modest portion sizes (Brownell, 2004; Wadden, Crerand, et 
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al., 2005). In addition to eliminating triggers to overeating, patients are instructed to add 
cues to their environment that promote healthful behaviors. For example, placing a pair 
of sneakers at the front door may serve as a prompt to exercise. Patients are encouraged 
to use self-reinforcement techniques, such as non-food-related rewards, to strengthen the 
frequency of these behaviors (Brownell, 2004; Dietz & Robinson, 2005; Nauta et al., 
2001).  
In addition to limiting their energy intake, patients are instructed to increase their 
energy expenditure through physical activity. While physical activity alone is of limited 
benefit in inducing weight loss, it is a critical component in the long-term management of 
weight (Jakicic & Otto, 2005; Wadden, McGuckin, Rothman, & Sargent, 2003; Wing, 
1999). Patients who exercise on a regular basis after losing weight are more likely to 
maintain their losses than are those who do not exercise regularly after losing weight 
(Wadden et al., 2003). Similarly, patients who achieve greater amounts of physical 
activity (e.g., 2,500 kcal/week or greater) are more likely to maintain their losses 
compared with those who achieve lesser amounts of physical activity (Jakicic, Winters, 
Lang, & Wing, 1999; Jeffery, Wing, Sherwood & Tate, 2003). Exercise confers 
important health benefits, such as reducing lipid levels, blood pressure, blood glucose, 
and risk of osteoporosis (Jakicic & Otto, 2005). In addition, it appears to reduce 
cardiovascular morbidity and mortality, independent of weight loss outcomes (Hu et al., 
2004; Lee, Blair, & Jackson, 1999; Wadden, Butryn, & Byrne, 2004).  
Behavior therapy encourages patients to increase their programmed activity and 
lifestyle activity (Brownell, 2004; Wadden, Crerand, et al., 2005). Programmed activity is 
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defined as structured bouts of exercise, completed in discrete periods of time (i.e., 30 to 
60 minutes) at a relatively high intensity (i.e., 60 to 80% of maximum heart rate) 
(Fabricatore & Wadden, 2006). Examples of programmed activity include jogging, 
biking, swimming, and scheduled workouts. In contrast, lifestyle activity refers to activity 
performed as part of one’s daily routine (Brownell, 2004). Lifestyle activity includes 
walking instead of driving, using stairs instead of elevators, and parking farther from 
building entrances (to achieve more steps). Studies suggest that lifestyle activity may be 
as effective as traditional structured exercise in improving fitness and weight control 
(Andersen et al., 1999; Dunn et al., 1999). Lifestyle activity also requires less planning 
and time commitment than does programmed activity. Thus, lifestyle activity may 
represent an attractive alternative for patients who do not enjoy or have time to engage in 
structured exercise.  
Behavior therapy traditionally prescribes 1,000 kcal/week in physical activity, 
which is roughly equivalent to walking 10 miles per week. Patients who have difficulty 
achieving this goal are encouraged to schedule exercise in multiple bouts. Jakicic, Wing, 
Butler, and Robertson (1995) found that subjects who were instructed to engage in 
multiple, shorter bouts of activity (i.e., four 10-minute bouts of activity) demonstrated 
better exercise adherence and weight loss at 6 months than those who were instructed to 
engage in single, longer bouts of activity (i.e., one 40-minute bout). Scheduling exercise 
in multiple bouts may be especially helpful to patients who are unaccustomed to 
exercising on a regular basis or to those who are initiating an exercise program for the 
first time.   
CHANGES IN APPETITE AND EATING BEHAVIOR 33                 
                                                                                                                                                                                                     
Research suggests that completing 2,000 to 2,500 kcal/week in physical activity 
(e.g., walking 20 to 25 miles per week) results in better weight control than does 
completing 1,000 kcal/week, as prescribed in traditional behavior therapy (Jakicic et al., 
1999; Jeffery et al., 2003; Tate, Jeffery, Sherwood, & Wing, 2007). In 2002, the Institute 
of Medicine recommended at least 60 minutes per day of moderate activity to manage 
body weight and avoid weight gain, which subsequently was reflected in the 2005 
Dietary Guidelines for Americans (HHS/ USDA, 2006). Sixty minutes of moderate 
activity per day translates to approximately 2,100 kcal/week in exercise, which is double 
the recommended dose of physical activity in behavior therapy. Further support of higher 
amounts of physical activity comes from members of the National Weight Control 
Registry, a list of persons who have lost at least 13.6 kg (i.e., 30 lb) and have maintained 
this loss for at least 1 year (Klem, Wing, McGuire, Seagle, & Hill, 1997). Members 
report an average of 2,800 kcal/week in physical activity, which is roughly equivalent to 
walking 28 miles per week. The dose of exercise traditionally prescribed in behavior 
therapy, therefore, appears to be lower than the dose found to ensure long-term weight 
control.  
 Because the goal of behavior therapy is permanent weight loss, patients must 
remain motivated to control their weight beyond the course of treatment. Unfortunately, 
few patients who lose weight are able to maintain their losses over time (Wadden, 
Crerand, et al., 2005). Within the first year following behavior therapy, patients tend to 
regain 30 to 35% of weight initially lost in treatment, and over 50% of individuals return 
to their baseline weight within 5 years (Wadden, Crerand, et al., 2005). It is difficult for 
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patients to practice healthful behaviors consistently in face of the variety of compensatory 
biological and environmental forces that oppose weight loss (Aronne, Wadden, Isoldi, & 
Woodworth, 2009; Brownell, 2010). Helping patients remain motivated to control their 
weight, given these conditions, represents a final target in behavior therapy. 
 The construct of social support has been studied widely in health behavior 
research in terms of its effects on a variety of medical and psychological conditions 
(Gallant, 2003; McNeill, Kreuter, & Subramanian, 2006). In terms of its impact on 
obesity management, Gorin et al. (2005) found that subjects with at least one support 
partner who had been successful in losing weight displayed greater weight loss at 6, 12, 
and 18 months than those with no successful partners or those without partners. In 
another study, 66% of subjects who participated in a behavioral weight loss program with 
three friends maintained their weight losses at 6-month follow-up, compared with only 
24% who participated in treatment alone (Wing & Jeffery, 1999). Research also shows 
that social support is positively correlated with exercise behavior and exercise intention 
(Carron, Hausenblas, & Mack, 1996) and that social support independently affects 
exercise behavior (Fraser & Spink, 2002). Having someone with whom to exercise, for 
example, increases the probability that one will engage in physical activity (Der Ananian, 
Wilcox, Saunders, Watkins, & Evans, 2006). Based on these findings, social support 
appears to facilitate weight control and may help sustain motivation in the long term.   
Pharmacotherapy 
Pharmacotherapy represents another approach to the management of obesity. The 
use of medications is indicated for patients with a BMI equal to or greater than 30 kg/m
2
, 
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or with a BMI of 27 to 29.9 kg/m
2
 in the presence of obesity-related medical conditions 
(NHLBI, 2000). Consistent with a stepped-care approach to weight management, 
medication typically is reserved for patients who have failed to lose weight with diet, 
exercise, and behavior therapy (Phelan & Wadden, 2002).  
The introduction of weight loss medication originally was heralded by the 
medical community as representing a very promising method of treating obesity. 
Unfortunately, hopes were derailed after a series of adverse events was observed in 
association with several agents. In 1934, for example, dinitrophenol was pulled from the 
market because of its link with cataract and neuropathy (Masserman & Goldsmith, 1934). 
The use of amphetamine has been banned, restricted, or discouraged because of its 
potential for abuse or dependence (Huizinga, 2007). Common over-the-counter 
medications, such as those containing the ephedra herb, have been removed from shelves 
because of health risks associated with their usage (Huizinga, 2007). Perhaps the most 
infamous weight loss medication was fenfluramine, which was withdrawn from the 
market in 1997 because of its link with potentially fatal heart valve abnormalities 
(Connolly et al., 1997).   
 Despite a history of safety concerns, newer (and presumably safer) weight loss 
medications continue to be developed and prescribed (Huizinga, 2007). These 
medications serve to reduce food intake, affect nutrient absorption, and/or increase 
energy expenditure. Several anorectic agents are approved by the FDA for short-term use 
(generally 12 weeks or less), such as phentermine, diethylpropion, and phendimetrazine 
(Huizinga, 2007). These agents generally affect the availability of anorexigenic 
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neurotransmitters (most notably, norepinephrine, serotonin, and dopamine) in the central 
nervous system, which in turn suppresses appetite. The only medication that is currently 
approved for the long-term management of obesity is orlistat, a gastric and pancreatic 
lipase inhibitor that reduces the absorption of dietary fat consumed in meals by 
approximately 30% (Li et al., 2005). 
Until recently (and during the time of the current study), sibutramine also was 
approved for the long-term management of obesity. Sibutramine is a beta-
phenylethylamine that inhibits the reuptake of serotonin (5-HT) and norepinephrine (NA) 
(as well as of dopamine to a very limited extent), thereby increasing their extracellular 
levels. The 5-HT2A/2C, 5-HT2B/2C, and 5-HT1A receptors have been implicated in 
mediating the action of sibutramine on food intake (Jackson, Neeham, Hutchins, 
Mazurkiewicz, & Heal, 1997; Stricker-Kongrad, Souquet, Jackson, & Burlet, 1996). 
Research has shown that 5-HT1A antagonists reduce meal size, 5-HT2A/2C agonists 
fragment the meal, and 5-HT2C agonists decrease rate of ingestion (Chapelot, Marmonier, 
Thomas, & Hanotin, 2000). A synergy between the action of sibutramine on 5-HT and 
NA reuptake also has been found to contribute to the potent effect of the drug (Jackson, 
Pleasance, & Heal, 1998). These actions appear to modify internal hunger and satiation 
cues (Bray, 2002), thereby facilitating adherence to a reduced-calorie diet. In conjunction 
with reducing appetite, sibutramine has been shown to increase resting metabolic rate and 
limit the decline in energy expenditure associated with weight loss (Persky et al., 2004; 
Walsh, Leen, & Lean, 1999). In total, the effect of sibutramine on weight loss appears to 
be mediated by both decreased energy intake and increased energy expenditure. 
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The efficacy of sibutramine has been established in more than a dozen placebo-
controlled studies (Arterburn, Crane, & Veenstra, 2004). The use of sibutramine has been 
shown to produce losses of 5 to 8% of initial weight over the first 6 months of treatment, 
compared with 1 to 4% with placebo (Bray et al., 1999; Fanghanel, Cortinas, Sanchez-
Reyes, & Berber, 2000; Fujioka et al., 2000; Ryan, 2000). At 1 year, sibutramine has 
been associated with losses of 7 to 10% of initial weight (Bray, 2007). Findings from the 
Sibutramine Trial of Obesity Reduction and Maintenance (STORM) indicate that 
sibutramine also facilitates the maintenance of lost weight for up to 2 years (James et al., 
2000). Research has found no significant difference in weight reduction among patients 
treated with sibutramine continuously compared with those treated intermittently over a 
period of 48 weeks (Wirth & Krause, 2001), suggesting that the intermittent use of the 
drug could save costs without sacrificing efficacy. Finally, in conjunction with weight 
loss, sibutramine has been shown to confer significant benefits in improving metabolic 
outcomes and reducing cardiovascular risk factors (Vettor, Serra, Fabris, Pagano, & 
Federspil, 2005). 
Owing to its sympathomimetic properties, the use of sibutramine is associated 
with increased pulse rate (4 to 5 beats per minute) and increased systolic and diastolic 
blood pressure (1 to 3 mmHg) (Bray, 2002). Thus, it is contraindicated for patients with 
uncontrolled hypertension or cardiovascular disease, such as coronary artery disease, 
cerebrovascular disease, cardiac arrhythmia, and congestive heart failure. Sibutramine 
also is contraindicated for those who are already taking medications that inhibit serotonin 
reuptake. Unlike fenfluramine and amphetamine, respectively, sibutramine has not been 
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implicated in the development of valvular heart disease (since it does not stimulate 
serotonin release) and has very low abuse potential (since it does not enhance dopamine 
release) (Bray, 2002).  
Surgical Treatments 
Weight loss surgery, known as bariatric surgery, represents the last resort for 
weight loss in most cases. It generally is reserved for patients with a BMI equal to or 
greater than 40 kg/m
2
, or with a BMI of 35 to 39.9 kg/m
2
 in the presence of obesity-
related medical comorbidities (NHLBI, 2000). Bariatric surgery essentially involves 
reducing the size of the stomach, thus limiting calorie intake and producing significant 
weight loss. Surgical intervention is demonstrated to be the most effective means of 
inducing and maintaining weight loss in extremely obese patients, displaying the capacity 
to improve or ameliorate several weight-related conditions (e.g., hypertension, type 2 
diabetes, obstructive sleep apnea) (Buchwald et al., 2004).  
The most common types of bariatric surgery performed in the United States are 
gastric bypass and gastric banding (Buchwald, 2005; Steinbrook, 2004). Gastric bypass 
surgery consists of separating the upper part of the stomach and its connection to the 
midpart of the small intestine, allowing for food to bypass most of the stomach and the 
first part of the small intestine. The smaller gastric pouch leads to a faster sensation of 
satiety, while the bypass of the small intestine results in a limited absorption of calories 
(and other nutrients). Patients who undergo this procedure must be monitored long term 
for micronutrient deficiencies resulting from the malabsorptive effects of surgery 
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(Ledoux et al., 2006). Expected weight loss with gastric bypass is approximately 65 to 
70% of excess body weight and approximately 35% of BMI (Buchwald, 2005).  
Gastric banding surgery consists of placing a silicone band around the upper part 
of the stomach, thus creating a small stomach pouch and restricting the amount of food 
consumed. Unlike the effects of gastric bypass, gastric banding does not limit the 
absorption of nutrients. The silicone band is also adjustable and reversible (if necessary). 
Weight loss outcomes are approximately 50% of excess body weight and approximately 
25% of BMI (Buchwald, 2005). While gastric banding tends to result in smaller (yet still 
significant) weight loss than gastric bypass, the former is associated with lower 
complication and mortality rates. The risk of operative mortality from gastric bypass is 
about 0.5%, whereas the operative mortality risk from gastric banding is about 0.1% 
(Buchwald, 2005). With either procedure, patients must adhere to the postoperative diet 
in order to achieve and maintain optimal weight loss (NHLBI, 2000). 
Combination of Pharmacotherapy and Behavior Therapy 
The combination of pharmacotherapy and behavior therapy has been found to 
produce greater weight loss than either approach alone (Wadden et al., 2001; Wadden, 
Berkowitz, et al., 2005). The superior weight loss achieved with combining these 
therapies may be attributable to their complementary mechanisms of action. Medication 
appears to modify internal signals that regulate appetite (Bray, 2002), while behavior 
therapy helps patients control the external food environment (Foster et al., 2005; 
Wadden, Crerand, et al., 2005). When combined, these therapies are believed to address a 
greater number of variables than when used alone, which consequently enhances weight 
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loss (Wadden, Butryn, et al., 2007). Earlier investigations that compared fenfluramine 
and lifestyle modification found that patients who received lifestyle modification 
displayed greater improvements in eating behaviors, cognitions, and adherence to eating 
schedules (Craighead, 1984; Craighead & Agras, 1991). Another study found that those 
treated with the combination of phentermine and fenfluramine displayed greater 
improvements in hunger and evening fullness compared with those who received lifestyle 
modification (Weintraub et al., 1992). These findings suggest that pharmacotherapy and 
behavior therapy indeed target different variables.  
Walker, Ballard, and Gold (1977) and Brightwell and Naylor (1979) were among 
the first groups of investigators to demonstrate the benefits of adding medication 
(mazinol and phentermine, respectively) to a behavior modification program for the 
management of obesity. These studies, however, were flawed by limitations in 
experimental design, sample size, and therapeutic response. Craighead, Stunkard, and 
O’Brien (1981) are credited with conducting the first large-scale, randomized controlled 
trial that demonstrated the additive effects of medication and behavior therapy. They 
found that patients treated with fenfluramine (120 mg/day), in brief monthly office visits, 
lost an average of 7% of initial weight in 6 months, compared with a loss of 11% among 
those treated with weekly group behavior therapy. Patients treated with the combination 
of medication and group behavior therapy lost an average of 16% of initial weight, a 
significantly greater loss than achieved with either approach alone. Unfortunately, the 
clinical significance of these findings was limited by the subsequent withdrawal of 
fenfluramine in 1997.   
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 In 2001, Wadden et al. examined the weight losses associated with the 
combination of sibutramine and behavior therapy. Fifty-three obese women were 
randomly assigned to one of three groups, all of which received 1 year of treatment. 
Subjects in the first condition were prescribed sibutramine (15 mg/day) and received no 
formal instruction on modifying their eating and physical activity behavior, apart from 
being instructed to consume 1,200 kcal/day and to exercise regularly. Subjects in the 
second condition received sibutramine (15 mg/day) and were prescribed the same diet 
and exercise goals as the first condition. However, those in the second group attended 
behavior therapy on a weekly basis during the first 4 months of the study and on a 
monthly basis from months 5 to 12. Subjects in the third condition received the same 
intervention as the second condition but were also instructed to consume for the first 4 
months a portion-controlled diet of 1,000 kcal/day, consisting of liquid meal replacement 
products (OPTIFAST 800) and frozen-food entrees.    
Subjects who were treated with sibutramine alone lost 4.1% of initial weight at 
the end of 1 year, compared with a loss of 10.8% in subjects who were treated with 
sibutramine and behavior therapy. Those who received medication in combination with 
behavior therapy and the portion-controlled diet lost 16.5% of initial weight. Patients who 
received medication and behavior therapy achieved a significantly greater percentage of 
their expected weight loss and were more satisfied with changes in their weight, health, 
body image, and self-esteem than those treated with sibutramine alone. The results of this 
trial suggested that optimal weight loss and outcome satisfaction are achieved when 
pharmacotherapy is prescribed in conjunction with major lifestyle changes.  
CHANGES IN APPETITE AND EATING BEHAVIOR 42                 
                                                                                                                                                                                                     
More recently, Wadden, Berkowitz, et al. (2005) found similar results with the 
combination of sibutramine and behavior therapy. In addition, they demonstrated the 
efficacy of providing lifestyle modification to obese patients treated with sibutramine in 
primary-care practice. Two hundred and twenty-four obese adults (BMI = 30 to 45 
kg/m
2
), ages 18 to 65 years, were randomly assigned to one of four groups, all of which 
received 1 year of treatment: (a) 15 mg of sibutramine per day, delivered by a primary-
care provider (PCP) in eight visits of 10 to 15 minutes each; (b) lifestyle modification, 
provided by a trained psychologist in 30 group sessions of 90 minutes each; (c) 
combination of sibutramine (15 mg/day) and lifestyle modification, following the 
implementation of each therapy combined; and (d) sibutramine (15 mg/day) with brief 
lifestyle modification counseling delivered by a PCP in eight visits of 10 to 15 minutes 
each.  
The subjects who received sibutramine alone met with their PCPs at weeks 1, 3, 
6, 10, 18, 26, 40, and 52. They received a pamphlet that provided tips for healthy eating 
and physical activity, along with general encouragement from their PCPs, but received no 
formal weight loss counseling. Patients who received behavior therapy, alone and in 
combination with sibutramine, attended group meetings on a weekly basis from weeks 1 
to 18, meetings conducted every other week from weeks 20 to 40, and a follow-up visit at 
week 52. Subjects in these groups followed The LEARN Program for Weight Control 
(Brownell, 1998) for the first 18 weeks of the study, and The Weight Maintenance 
Survival Guide (Brownell & Rodin, 1990) from weeks 20 through 40. These manuals 
provide detailed instruction on the behavioral management of obesity in a user-friendly 
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manner. Patients who received the combination of sibutramine and behavior therapy 
attended medical visits on the same schedule as those who received sibutramine alone 
and followed The LEARN Program for Weight Control: Special Medication Edition 
(Brownell & Wadden, 1999), which is specifically designed for the concurrent use of 
sibutramine. Finally, subjects who received sibutramine and brief PCP counseling met 
with their PCP on the same weeks as those who received sibutramine alone but were 
instructed to follow The LEARN Program for Weight Control: Special Medication 
Edition (Brownell & Wadden, 1999) and The Weight Maintenance Survival Guide 
(Brownell & Rodin, 1990) on their own and to review their progress with their PCP at 
each visit. Subjects in all four conditions were prescribed a diet of 1,200 to 1,500 
kcal/day and were encouraged to exercise (i.e., walk) 30 minutes per day on most days of 
the week. 
At 1 year, subjects who received the combination of sibutramine and behavior 
therapy (combined therapy) lost a mean of 12.1 kg (SD = 9.8 kg), compared with a mean 
loss of 5.0 kg (SD = 7.4 kg) among those treated with sibutramine alone, 6.7 kg (SD = 7.9 
kg) among those treated with behavior therapy alone, and 7.5 kg (SD = 8.0 kg) among 
those treated with sibutramine and brief PCP counseling. Subjects who received 
combined therapy lost significantly more weight at weeks 18, 40, and 52 than those in the 
other three conditions. The mean weight loss of subjects who received combined therapy 
approximately doubled the loss of those who received sibutramine or behavior therapy 
alone at 1 year. Significantly more subjects in the combined therapy group lost 5% or 
more (as well as 10% or more) of their initial weight than did those in the other three 
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groups. Although there were no significant differences in changes in cardiovascular risk 
factors among the four groups, weight loss at week 52 was correlated with improvements 
in triglyceride levels, insulin levels, HDL cholesterol levels, insulin resistance, and 
systolic and diastolic blood pressure.  
Based on these results, Wadden, Berkowitz, et al. (2005) concluded that greater 
weight loss is achieved when sibutramine is used in conjunction with a comprehensive 
program of diet, exercise, and behavior therapy. The success of this approach was 
believed to be attributable to the additive effects of sibutramine and behavior therapy. 
Sibutramine appears to modify the internal environment related to appetite (Bray, 2002), 
while behavior therapy appears to modify the external environment related to food 
(Foster et al., 2005; Wadden, Crerand, et al., 2005). Evidence suggests that sibutramine 
and behavior therapy have these separate effects (Bray, 2002; Foster et al., 2005; 
Wadden, Crerand, et al., 2005). However, no study has assessed the potentially 
complementary mechanisms of action of sibutramine and behavior therapy in a trial that 
examines these therapies separately and combined.  
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Chapter Three: Hypotheses 
Overall Question 
 The current study was guided by the following question – Is the combination of 
sibutramine and behavior therapy associated with improvements in appetite control and 
eating behavior? To answer this question, changes in appetite and eating behavior were 
compared across three conditions: (a) sibutramine (15 mg/day), (b) behavior therapy (18 
group sessions), and (c) combination of sibutramine (15 mg/day) and behavior therapy 
(18 group sessions).  
Hypothesis 1 
Ho. There is no difference in eating behavior between subjects treated with 
behavior therapy, whether alone or in combination with sibutramine, and those treated 
with sibutramine alone.  
H1. Subjects who receive behavior therapy, whether alone or in combination with 
sibutramine, will display more appropriate eating behavior than those who receive 
sibutramine alone.  
Rationale. Behavior therapy facilitates the adoption of healthy eating and 
physical activity behaviors through the application of empirically supported principles 
and techniques. It teaches patients to control external eating-related cues by such methods 
as storing foods out of sight, avoiding high-risk situations (e.g., fast-food restaurants), 
and limiting activities while eating (e.g., watching television). It also provides strategies 
to control eating in response to social or emotional cues (Foster et al., 2005; Wadden, 
Crerand, et al., 2005). Therefore, subjects who receive behavior therapy, whether alone or 
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in combination with sibutramine, are expected to display more appropriate eating 
behavior (i.e., theoretically facilitative of weight control) than those who receive 
sibutramine alone. 
Hypothesis 2 
Ho. There is no difference in appetite control between subjects treated with 
sibutramine, whether alone or in combination with behavior therapy, and those treated 
with behavior therapy alone.  
H1. Subjects treated with sibutramine, whether alone or in combination with 
behavior therapy, will achieve significantly better appetite control than those treated with 
behavior therapy alone. 
Rationale. Sibutramine is a beta-phenylethylamine that inhibits the reuptake of 
serotonin and norepinephrine (as well as of dopamine to a very limited extent), thereby 
increasing their extracellular levels. It appears to modify biological variables related to 
appetite, such as levels of hunger and satiation (Bray, 2002). These actions appear to 
reduce patients’ responsiveness or vulnerabilities to food cues. Therefore, subjects treated 
with sibutramine, whether alone or in combination with behavior therapy, are expected to 
display better appetite control (i.e., less food preoccupation, fewer cravings, less hunger, 
more fullness) than those treated with behavior therapy alone.   
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Chapter Four: Methods 
Design and Design Justification 
 The study utilized an archival-data design. The data originally were collected as 
part of a randomized controlled trial (Wadden, Berkowitz, et al., 2005), as described 
previously, that examined weight loss associated with the provision of sibutramine, 
behavior therapy, the combination of sibutramine and behavior therapy, and sibutramine 
plus brief lifestyle counseling by a PCP. Only the results of the subjects who received 
sibutramine (15 mg/day), behavior therapy (18 group sessions), and the combination of 
sibutramine (15 mg/day) and behavior therapy (18 group sessions) in the original trial 
were analyzed in the current study. The results of those who received sibutramine plus 
brief lifestyle counseling by a PCP in the original trial were excluded from the analysis in 
order to limit the number of statistical comparisons (thus preserving the alpha level). In 
addition, the current study examined data from only the first 18 weeks of the original, 12-
month trial, since the most reliable data were likely to have been reported by subjects 
during the initial period of treatment (i.e., months 1 to 5). 
Participants 
 The participants consisted of subjects who participated in three of the four 
conditions of the original trial, as described under Design and Design Justification. The 
sample included 136 women and 35 men (N = 171), who were randomly assigned to 
receive sibutramine (n = 56), behavior therapy (n = 55), or the combination of 
sibutramine and behavior therapy (n = 60). All subjects were between the ages of 18 and 
65 years and had a BMI of 30
 
to 45 kg/m
2
 at the start of the original trial.  
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Inclusion/Exclusion Criteria  
The subjects who were eligible to participate in the original trial were free of 
uncontrolled hypertension (i.e., blood pressure greater than 140/90 mmHg); 
cerebrovascular, cardiovascular, renal, or hepatic disease; and type 1 or type 2 diabetes. 
Psychosocial contraindications included bulimia nervosa, substance abuse, clinically 
significant depression, and current psychiatric treatment. The use of medications known 
to affect body weight, a weight loss of 5 kg or greater in the preceding 6 months, and the 
use of selective serotonin-reuptake inhibitors were additional exclusion criteria. Women 
who were pregnant or breast-feeding at the time of screening also were ineligible for the 
study.  
Screening Procedures to Determine Inclusion/Exclusion Criteria 
 Subjects of the original trial were screened initially by telephone to determine if 
they met the inclusion/exclusion criteria. Telephonic screening was conducted by 
bachelor’s-level research assistants following a written protocol. Applicants who met the 
inclusion/exclusion criteria by telephone were scheduled for an on-site interview with a 
clinical psychologist at the Weight and Eating Disorders Program (WEDP) at the 
University of Pennsylvania. During this interview, applicants were informed of the 
requirements of the study and were asked to provide their informed consent to participate. 
Those who consented proceeded with the screening process, which included a medical 
evaluation by the applicants’ family physicians and a behavioral evaluation by a clinical 
psychologist at the WEDP. Candidates who did not meet entry criteria for the study were 
offered a referral to an appropriate program.  
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Recruitment 
 Subjects were recruited for the original trial through the use of public service 
announcements, notices in local newspapers, and referrals from PCPs in the University of 
Pennsylvania Health System.  
Plan for Informed Consent Procedures 
 Informed consent from the subjects of the original trial was not required for the 
current study.     
Measures 
Eating behavior. The Eating Behavior Inventory (EBI) (O’Neil et al., 1979) was 
used to assess changes in the practice of weight control behaviors among the three 
groups. The EBI is a 26-item, self-report scale that is designed to assess behaviors 
theoretically implicated in weight loss, such as recording food intake, eating slowly, and 
shopping from a food list (see Appendix A). Items are constructed in the form of first-
person statements. Examples include, “I carefully watch the quantity of food that I eat,” 
“I eat at only one place in my home,” and “I decide ahead of time what I will eat for 
meals and snacks.” Each item is rated on a 5-point scale according to how often the item 
is true for the respondent, using the following key: 1 = never or hardly ever, 2 = some of 
the time, 3 = about half of the time, 4 = much of the time, and 5 = always or almost 
always. Higher numerical scores reflect more appropriate eating behavior (theoretically 
facilitative of weight control) than lower numerical scores. The total numerical score 
provides an index of overall appropriateness of eating behavior.  
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 The EBI generally is a valid, internally consistent, and temporally stable measure 
of eating behavior (O’Neil et al., 1979; O’Neil & Rieder, 2005). The validity of the scale 
(individual items and total score) has been demonstrated through several studies, which 
show correlations between self-reported scores and scores of others who are familiar with 
the subjects’ behaviors; correlations between self-reported scores and self-monitoring 
data; and sensitivity of self-reported scores to behavioral weight loss treatment (O’Neil et 
al., 1979; O’Neil & Rieder, 2005). The EBI has a split-half reliability of 0.62 (p < 0.001), 
and all but one item correlate significantly with total score. With the exception of two 
items, which have exceedingly small variances, test-retest reliability of items ranges from 
0.36 to 0.83, with a median of 0.63 (p’s < 0.01). Total score test-retest reliability is 0.74 
(p < 0.01) (O’Neil et al., 1979).  
Appetite. Visual analogue scales (Womble, Wadden, Chandler, & Martin, 2003), 
which have been used to measure appetite since the 1960s (Jordan, Wieland, Zebley, 
Stellar, & Stunkard, 1966; Silverstone & Stunkard, 1968), were used to assess changes in 
appetite among the three groups. These scales are composed of 100-millimeter lines with 
two extreme states anchored at each end (see Appendix B). For example, the question, 
“How hungry have you felt over the past 24 hours?” is anchored by “Not at all hungry” at 
one end and “Extremely hungry” at the other end. Subjects are instructed to make a 
vertical mark across the line corresponding to their level of appetite. Quantification of 
measurements is done by measuring the distance from the left end of the line to the mark.  
Four variables of appetite were assessed in the current study, based on their 
selection in previous studies of appetite (e.g., Wadden et al., 1997; Womble et al., 2003). 
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These variables included food preoccupation (amount of time spent thinking about food), 
cravings (intense desire to consume a particular food), satiation (sensation of fullness), 
and hunger (drive to eat). Food preoccupation was assessed through the question, “How 
much were you bothered or distracted by thoughts of food over the past 24 hours?” (Not 
all all/Extremely bothered); cravings were measured through, “How often did you 
experience craving to eat particular types of foods over the past 24 hours?” (Not at 
all/Extremely frequently); satiation was assessed through, “How full did you feel after 
consuming your meals over the past 24 hours?” (Not at all full/Extremely full); and 
hunger was measured through, “How hungry have you felt over the past 24 hours?” (Not 
at all hungry/Extremely hungry).  
The validity of these scales has been demonstrated through findings that hunger 
ratings decrease, while satiation ratings increase, immediately after a laboratory test meal 
(Blundell & Rogers, 1980); that appetite ratings differ significantly, in anticipated 
directions, between subjects treated with weight loss medications and placebo (Blundell 
& Rogers, 1980; Weintraub, Hasday, Mushlin, & Lockwood, 1984); and that appetite 
ratings correlate significantly with the hunger subscale of the Eating Inventory (Womble 
et al., 2003), a psychometrically sound measure of hunger (Stunkard & Waterland, 1997). 
Test-retest reliability of the scales is acceptable (r = 0.61 – 0.85) (Flint, Raben, Blundell, 
& Astrup, 2000). More recent findings demonstrate excellent test-retest reliability for 
most scales (r = 0.78 – 0.95) when administered in the short term (i.e., 90 minutes apart) 
(Womble et al., 2003). These scales have the advantages of being quick, easy to use, and 
simple to interpret (Stubbs et al., 2000). They also do not require subjects to invoke their 
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own descriptive terms for the variables being measured and are presented in a 
standardized format that can be compared under a variety of different experimental 
manipulations (Stubbs et al., 2000). 
Procedure 
The procedures of the original trial were described in Chapter Two. The subjects 
completed the EBI and the visual analogue scales during their clinic visits, which 
primarily were scheduled in the evening (at the WEDP). The EBI was administered at 
baseline and week 18, and the visual analogue scales were administered at baseline, week 
3, week 6, week 10, and week 18. Scores from these instruments were calculated and 
inputted into a computer database. Upon receiving permission from the principal 
investigator of the original trial, Thomas A. Wadden, Ph.D., these data were analyzed in 
accordance with the goals of the current study.   
Analysis of Risk/Benefit Ratio 
Potential risk to participants. There was no risk to the subjects of the current 
study because of its archival-data design. 
Potential benefit to participants. There was no benefit to the subjects of the 
current study because of its archival-data design. 
Potential benefit to others. Results of the current study may potentially benefit 
patients who are obese by improving the management of obesity in primary-care practice. 
As expected, improvements in both appetite control and eating behavior were found to 
account for the greater weight loss achieved with the combination of sibutramine and 
behavior therapy than with either approach alone. Our findings underscore the 
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importance of using pharmacotherapy in conjunction with a comprehensive program of 
diet, exercise, and behavior therapy, as recommended by the NHLBI (1998). Our results 
may encourage PCPs to prescribe weight loss medications in combination with, rather 
than in lieu of, lifestyle modification, perhaps with the assistance of behavioral health 
providers integrated within the practice. The outcomes of this study, therefore, may serve 
to improve the quality of care and subsequent health of obese patients. 
Procedure for Maintaining Confidentiality 
 To ensure patient privacy, the charts of the subjects who participated in the 
original trial remained in a locked filing cabinet at the Center for Weight and Eating 
Disorders (formerly the WEDP) at the University of Pennsylvania for the duration of the 
current study. In addition, code numbers were assigned to each subject to maximize 
anonymity while analyzing the data.  
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Chapter Five: Results 
Statistical Analyses 
The sample used in the present study was a subset of a larger trial that compared 
weight loss among four different conditions over 1 year (Wadden, Berkowitz, et al., 
2005). Analysis of variance revealed no significant differences among the groups in 
baseline characteristics (see Table 1). The aims of the current study were tested using 
mixed effects linear model analysis for repeated measures (SAS, Version 9.2 for 
Windows; SAS Institute, Inc., Cary, NC). For Aim 1, the primary outcome was change in 
eating behavior among subjects who received sibutramine alone, behavior therapy alone, 
and combined therapy, as assessed by change in total EBI scores from baseline to week 
18. The mixed model for this analysis included time (Baseline, Week 18) and treatment 
(Sibutramine Alone, Behavior Therapy Alone, Combined Therapy) as the main effects, 
and a time-by-treatment interaction term. For Aim 2, the primary outcome was change in 
appetite among the three conditions, as assessed by change in ratings on 100-mm visual 
analogue scales at four time points. Appetite was measured in terms of food 
preoccupation, cravings, satiation, and hunger. Partial-correlation analysis that controlled 
for treatment group indicated that these four appetite variables overlapped yet were 
conceptually distinct constructs (see Table 2). For each of these variables, change scores 
were created by subtracting the ratings at baseline from the ratings at week 3, week 6, 
week 10, and week 18. The mixed model for this analysis included time (Week 3, Week 
6, Week, 10, Week 18) and treatment (Sibutramine Alone, Behavior Therapy Alone, 
Combined Therapy) as the main effects, and a time-by-treatment interaction term. 
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Table 1 
 
Baseline Characteristics of Subjects in the Three Groups 
 
 
Variable 
 
 
 
Sibutramine 
alone 
(n = 56) 
 
Behavior therapy 
alone 
(n = 55) 
 
Combined 
therapy 
(n = 60) 
 
 
Sex  
(number of subjects) 
   
 
     Female 
 
45 
 
42 
 
49 
 
     Male 
 
11 
 
13 
 
11 
 
Race or ethnicity  
(number of subjects) 
   
 
     White 
 
32 
 
35 
 
42 
 
     Black 
 
22 
 
18 
 
17 
 
     Hispanic 
 
2 
 
2 
 
1 
 
Age (years) 
 
42.2 ± 10.2 
 
43.3 ± 9.7 
 
44.2 ± 10.8 
 
Weight (kg) 
 
107.6 ± 14.8 
 
105.1 ± 17.0 
 
108.5 ± 18.6 
 
Height (cm) 
 
167.8 ± 7.7 
 
167.3 ± 8.4 
 
168.8 ± 9.2 
 
BMI (kg/m
2
) 
 
 
38.1 ± 3.9 
 
37.8 ± 4.2 
 
37.9 ± 4.2 
 
Note. Plus-minus values are means ± SD. There were no significant differences among  
 
the three groups on any of the baseline characteristics at p ≤ 0.05. Race or ethnicity was  
 
self-reported.  
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Table 2 
 
Correlations of Appetite Ratings Across the Three Groups at Baseline 
 
  
Hunger 
 
 
Food preoccupation 
 
 
Satiation 
 
Cravings 
 
Hunger 
 
1.0 
 
0.4* 
 
-0.1 
 
0.2* 
 
Food preoccupation 
 
0.4* 
 
1.0 
 
-0.1 
 
0.5* 
 
Satiation 
 
-0.1 
 
-0.1 
 
1.0 
 
-0.2 
 
Cravings 
 
0.2* 
 
0.5* 
 
-0.2 
 
1.0 
 
 
* Significant correlation at p ≤ 0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHANGES IN APPETITE AND EATING BEHAVIOR 57                 
                                                                                                                                                                                                     
Analysis of variance revealed no significant differences among the means of each 
appetite variable at baseline. Planned post-hoc pairwise comparisons of the appetite 
scores were conducted at each time point when significant treatment effects were found. 
For all analyses, results were considered significant at p ≤ 0.05. Data are presented as 
model-based means (± SE), unless otherwise indicated.  
Eating Behavior 
 The mean values (± SE) on the EBI of the three groups are displayed in Table 3. 
From baseline to week 18, the means increased from 60.1 ± 1.1 to 63.4 ± 1.2 among 
those who received sibutramine alone, from 63.0 ± 1.2 to 75.8 ± 1.2 among those who 
received behavior therapy alone, and from 61.3 ± 1.2 to 73.1 ± 1.1 among those who 
received combined therapy. There were significant differences in mean change from 
baseline among subjects who received sibutramine alone compared with those who 
received behavior therapy alone, F(1, 157) = 29.52, p < 0.0001, and combined therapy, 
F(1, 157) = 23.29, p < 0.0001. No significant difference in mean change was found 
between the behavior therapy alone and combined therapy conditions, F(1, 157) = 0.44,  
p = 0.51. These results clearly indicate an increase in the practice of weight control 
behaviors among those treated with behavior therapy.     
Appetite 
Food preoccupation. As shown in Table 4, there was a significant main effect of 
treatment for the variable of food preoccupation, F(2, 142) = 3.87, p = 0.02. The mean 
changes (± SE) from baseline, collapsed across time, were -3.6 ± 3.6 among those who 
received sibutramine alone and -4.8 ± 3.4 among those who received combined therapy.  
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Table 3 
 
Eating Behavior Inventory Scores at Baseline and Week 18 in the Three Groups 
 
 
Condition 
 
Baseline 
 
Week 18 
 
Change from baseline 
 
    
Sibutramine alone (n = 56) 60.1 ± 1.1 63.4 ± 1.2
 
3.3 ± 1.3
a 
 
Behavior therapy alone (n = 55) 63.0 ± 1.2 75.8 ± 1.2
 
12.9 ± 1.2
b 
 
Combined therapy (n = 60) 61.3 ± 1.1 73.1 ± 1.1
 
 
11.8 ± 1.2
b 
 
Note. Values are model-based means ± SE. 
 
 a, b 
Values labeled with different letters are significantly different from each other at  
 
p < 0.0001.  
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Table 4  
 
Changes in Appetite from Baseline During 18 Weeks of Treatment in the Three Groups 
 
 
Variable 
 
Sibutramine 
alone 
(n = 56) 
 
Behavior 
therapy alone 
(n = 55) 
 
Combined 
therapy 
(n = 60) 
 
 
Food preoccupation 
 
   
     Baseline  
 
42.4 ± 3.1 31.5 ± 3.3 39.3 ± 3.2 
     Week 3 
 
-4.7 ± 4.3
a 
7.5 ± 4.3
b 
-4.8 ± 4.1
a 
     Week 6 
 
-2.8 ± 4.4
ab 
8.2 ± 4.3
b 
-6.1 ± 4.1
a 
     Week 10 
 
-6.1 ± 4.2
a 
8.4 ± 4.1
b 
-6.8 ± 3.9
a 
     Week 18 
 
-0.9 ± 4.7 6.8 ± 4.6 -1.4 ± 4.3 
     All weeks from baseline combined -3.6 ± 3.6
a 
7.8 ± 3.5
b 
-4.8 ± 3.4
a 
    
Cravings 
 
   
     Baseline 
 
48.5 ± 3.6 49.0 ± 3.4 52.1 ± 3.0 
     Week 3 
 
-11.0 ± 4.4
a 
2.3 ± 4.4
b 
-13.9 ± 4.1
a 
     Week 6 
 
3.0 ± 4.4
a 
3.0 ± 4.4
a 
-11.7 ± 4.1
b 
     Week 10 
 
-4.6 ± 4.8
ab 
2.5 ± 4.7
a 
-13.1 ± 4.4
b 
     Week 18 
 
-7.3 ± 4.2 -1.7 ± 4.1 -7.0 ± 3.8 
     All weeks from baseline combined -4.9 ± 3.4
ab 
1.5 ± 3.4
a 
-11.4 ± 3.2
b 
    
Satiation 
 
   
     Baseline 
 
61.2 ± 2.9 67.2 ± 3.2 62.7 ± 2.9 
     Week 3 
 
5.9 ± 4.7
 
-8.8 ± 4.7
 
2.9 ± 4.4
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Variable 
 
Sibutramine 
alone 
(n = 56) 
 
Behavior 
therapy alone 
(n = 55) 
 
Combined 
therapy 
(n = 60) 
 
     
     Week 6 
 
 
-0.7 ± 3.7 
 
-10.0 ± 3.7 
 
-4.8 ± 3.5 
     Week 10 
 
0.4 ± 4.3 -10.4 ± 4.3 -1.6 ± 4.1 
     Week 18 
 
5.8 ± 4.7 -1.7 ± 4.6 -2.7 ± 4.2 
     All weeks from baseline combined 2.8 ± 3.5 -7.7 ± 3.6 -1.6 ± 3.4 
    
Hunger 
 
   
     Baseline 
 
50.0 ± 2.8 48.6 ± 2.9 48.7 ± 2.4 
     Week 3 
 
-12.2 ± 4.2 -3.1 ± 4.1 -6.0 ± 4.0 
     Week 6 
 
-5.4 ± 4.2 -3.0 ± 4.1 -8.9 ± 3.9 
     Week 10 
 
-10.0 ± 4.0 -1.6 ± 4.0 -8.3 ± 3.8 
     Week 18 
 
-2.4 ± 4.6 -3.3 ± 4.5 -5.0 ± 4.2 
     All weeks from baseline combined -7.5 ± 3.4 -2.7 ± 3.3 -7.1 ± 3.2 
 
 
Note. Values at baseline are raw means ± SE. Values at weeks 3, 6, 10, and 18 are model- 
 
based mean change scores from baseline ± SE.  
 
a, b
 Across each row, values labeled with different letters are significantly different from  
 
each other at p ≤ 0.05. Values without letters are not significantly different from the other  
 
values. 
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By contrast, the mean change of those who received behavior therapy alone was 7.8 ± 
3.5. These findings indicate, as expected, a decrease in food preoccupation among those 
who were treated with medication and an increase in food preoccupation among those 
who were not treated with medication. There were significant differences in mean change 
among subjects who received behavior therapy alone compared with those who received 
sibutramine alone, t(142) = -2.26, p = 0.03, and combined therapy, t(142) = -2.55,  
p = 0.01. No significant difference in mean change was found between the sibutramine 
alone and combined therapy conditions, t(142) = 0.23, p = 0.82. There was no significant 
main effect of time, F(3, 142) = 0.58, p = 0.63, nor a significant time-by-treatment 
interaction F(6, 142) = 0.47, p = 0.83. 
Post-hoc pairwise comparisons of the data at each time point revealed significant 
mean change differences from baseline between the behavior therapy alone and 
sibutramine alone conditions at week 3, t(142) = -2.0, p = 0.05, and at week 10,  
t(142) = -2.48, p = 0.01. The mean change of those treated with behavior therapy alone 
also differed significantly from the mean change of those treated with combined therapy 
at week 3, t(142) = -2.08, p = 0.04, and at week 10, t(142) = -2.68, p = 0.01. There was a 
significant difference in mean change between the behavior therapy alone and combined 
therapy conditions at week 6, t(142) = -2.41, p = 0.02. No significant mean change 
differences were found among the groups at week 18.  
Cravings. There was a significant main effect of treatment for the variable of 
cravings, F(2, 142) = 3.82, p = 0.02 (see Table 4). The mean changes (± SE) from 
baseline, collapsed across time, were -4.9 ± 3.4 among those who received sibutramine 
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alone and -11.4 ± 3.2 among those who received combined therapy. By comparison, the 
mean change of those who received behavior therapy alone was 1.53 ± 3.4. Thus, similar 
to ratings of food preoccupation, subjects who were given sibutramine showed a decrease 
in cravings, whereas cravings increased among those who were not given medication. 
Subjects who received combined therapy displayed a significantly different change in 
means compared with those who received behavior therapy alone, t(142) = -2.76,  
p = 0.01. The mean change difference between the sibutramine alone and behavior 
therapy alone conditions, however, failed to reach significance, t(142) = -1.34, p = 0.18. 
These findings suggest that receiving medication without lifestyle counseling resulted in 
suboptimal control of cravings. No significant difference in mean change was found 
between the sibutramine alone and combined therapy conditions, t(142) = 1.38, p = 0.17. 
There was no significant main effect of time, F(3, 142) = 1.98, p = 0.12, nor a significant 
time-by-treatment interaction F(6, 142) = 1.89, p = 0.09. 
 Post-hoc comparisons of the data at each time point revealed significant mean 
change differences from baseline to week 3 among subjects who received behavior 
therapy alone compared with those who received sibutramine alone, t(142) = -2.14, p = 
0.03, and combined therapy, t(142) = -2.71, p = 0.01. At week 6, those who received 
combined therapy displayed significant mean change differences compared with those 
who received behavior therapy alone, t(142) = -2.45, p = 0.02, and sibutramine alone, 
t(142) = 2.45, p = 0.02. At week 10, there was a significant mean change difference 
between the combined therapy and behavior therapy alone conditions t(142) = -2.42, p = 
0.02. No significant mean change differences were found among the groups at week 18.  
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Satiation. In contrast to ratings of food preoccupation and cravings, there was no 
significant main effect of treatment for the variable of satiation, F(2, 141) = 2.23,  
p = 0.11 (see Table 4). There was, however, a significant main effect of time, F(3, 141) = 
3.38, p = 0.02. The mean changes (± SE) from baseline, collapsed across the three 
groups, were -0.03 ± 2.6 at week 3, -5.2 ± 2.1 at week 6, -3.9 ± 2.5 at week 10, and 0.5 ± 
2.6 at week 18. The differences in mean change from baseline (with all groups combined) 
differed significantly from week 3 to week 6, t(141) = 2.33, p = 0.02, and from week 6 to 
week 18, t(141) = -2.47, p = 0.01. These findings indicate that subjects’ sensation of 
fullness generally decreased from week 3 to week 6, before increasing from week 6 to 
week 18. There was no significant time-by-treatment interaction, F(6, 141) = 0.97,  
p = 0.45.   
Hunger. With respect to the variable of hunger, results failed to yield a 
significant main effect of time, F(3, 142) = 0.77, p = 0.51, or treatment, F(2, 142) = 0.62, 
p = 0.54 (see Table 4). Likewise, there was no significant time-by-treatment interaction, 
F(6, 142) = 0.80, p = 0.57. The mean changes (± SE) from baseline, collapsed across 
time, were -7.5 ± 3.4 among those who received sibutramine alone, -2.7 ± 3.3 among 
those who received behavior therapy alone, and -7.1 ± 3.2 among those who received 
combined therapy.  
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Chapter Six: Discussion 
This archival-data study was designed to explore the potentially complementary 
mechanisms of action of sibutramine and behavior therapy in the treatment of obese 
patients. Wadden, Berkowitz, et al. (2005) previously demonstrated that combined 
therapy produced significantly greater weight loss than either therapy alone. However, 
the mechanisms of action through which this greater weight loss occurred remained 
unknown. Wadden and his team believed that the superiority of combined therapy was 
attributable to the additive effects of each approach. As described previously, sibutramine 
appears to modify biological variables related to appetite (Bray, 2002), while behavior 
therapy appears to modify the external environment related to food (Foster et al., 2005; 
Wadden, Crerand, et al., 2005). When combined, these therapies are believed to address a 
greater number of variables than when used alone, which consequently enhances weight 
loss (Wadden, Butryn, et al., 2007). However, no study had assessed the potentially 
complementary mechanisms of action of sibutramine and behavior therapy in a trial that 
examined these therapies separately and combined. 
We hypothesized that subjects who received behavior therapy, whether alone or in 
combination with sibutramine, would display more appropriate eating behaviors than 
those who received sibutramine alone. We also expected that those treated with 
sibutramine, whether alone or in combination with behavior therapy, would display better 
appetite control than those treated with behavior therapy alone. We aimed to better 
understand the mechanisms of action responsible for the greater weight loss achieved 
with combined therapy and, more broadly, to improve the quality of care provided to 
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obese patients in primary care. Although we failed to find significant differences across 
all measures of appetite, the majority of our findings were in the expected direction. Our 
results support the contention that sibutramine and behavior therapy work additively to 
produce greater weight loss than either approach alone. Therefore, our study expands 
upon the original trial by providing an empirically based account for the differences in 
weight loss among the groups.   
 With respect to eating behavior, patients who received behavior therapy alone or 
in combination with sibutramine displayed a significant increase in their practice of 
weight control behaviors compared with those who received medication alone (see Table 
3). Behavior therapy, as expected, appeared to effectively teach patients how to manage 
their external environment related to food. The effect of treatment was quite robust, as the 
scores of those treated with behavior therapy were three to four times greater than the 
scores of those treated with drug alone. As shown in Figure 1, Wadden, Berkowitz, et al. 
(2005) found that subjects who received behavior therapy, both alone and in combination 
with sibutramine, achieved significantly greater weight loss at week 18 than those who 
received medication alone. Our results expand on these findings by suggesting that the 
differences in weight loss between the groups were attributable, in part, to a greater 
increase in the practice of weight control behaviors among those treated with behavior 
therapy.  
We cannot identify the behaviors that were most affected by the behavioral 
intervention, as our primary aim was to examine changes in total score on the EBI.  
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Figure 1. Mean changes in weight (kg) from baseline during 18 weeks of treatment in the  
 
three groups, as determined by a last-observation-carried-forward analysis. 
 
 
 
However, a secondary analysis performed by the original authors (Wadden, Berkowitz, et 
al., 2005) showed that those who received behavior therapy alone or in combination with 
sibutramine completed significantly more food records than those who received 
medication alone and that keeping these records was positively correlated with weight 
loss. These findings indicate that those treated with behavior therapy increased their level 
of self-monitoring, which is a key component of treatment (Wadden, Crerand, et al., 
2005). That keeping food records was correlated with weight loss underscores the 
importance of modifying eating behaviors while attempting to lose weight, rather than 
relying solely on the effects of a medication (Wadden et al., 1997; Wadden, Berkowitz, et 
al., 2005).  
With respect to appetite, subjects who received sibutramine alone or in 
combination with behavior therapy reported significantly less preoccupation with food 
CHANGES IN APPETITE AND EATING BEHAVIOR 67                 
                                                                                                                                                                                                     
than those who received behavior therapy alone. Whereas ratings of food preoccupation 
decreased among patients treated with sibutramine, scores conversely increased among 
those treated with behavior therapy alone (see Figure 2). Thus, patients who did not 
receive sibutramine appeared to experience more bothersome thoughts about food, and 
thus poorer appetite control, than those who were treated with the medication. There was 
no significant difference in food preoccupation among those treated with sibutramine 
alone or in combination with behavior therapy, suggesting that the medication decreased 
food preoccupation equally among these subjects. 
As shown in Figure 3, patients who received combined therapy also appeared to 
experience significantly fewer cravings for food than those who received behavior 
therapy alone. By contrast, the cravings among those in the latter group increased slightly 
during treatment. Surprisingly, there was no significant difference in scores between the 
sibutramine and behavior therapy alone conditions, which was contrary to what we 
predicted. After differing in the expected directions at week 3, both groups rated their 
cravings equally at week 6, after which their scores split again in the expected directions. 
However, the difference in scores between these groups was not significant beyond week 
3. These results suggest that while sibutramine may reduce cravings to an extent, patients 
also must modify their behaviors (e.g., limit exposure to high-risk foods) if they wish to 
achieve optimal control. 
It is unclear why the reported cravings of those treated with sibutramine alone 
spiked from week 3 to week 6, as seen in Figure 3. One might argue that these subjects 
developed tolerance to the drug during these weeks. The prescribed dose of sibutramine   
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Figure 2. Mean changes (mm) in food preoccupation from baseline during 18 weeks of  
 
treatment in the three groups. 
 
 
 
increased from 5 to 10 mg at week 3, and from 10 to 15 mg at week 6. Subjects may have 
developed tolerance to the lower doses of the medication, and thus experienced fewer 
effects from week 3 to week 6, before being prescribed the higher dose at week 6. 
Research in rats has suggested that tolerance can develop to sibutramine (Wellman, 
Jones, & Miller, 2003). If subjects treated with medication alone had developed tolerance 
to the drug, then we would have expected a similar response pattern from those treated 
with combined therapy (since these subjects were administered the same doses as those 
treated with medication alone). However, the response patterns of these groups were 
inconsistent, suggesting that their scores likely were not affected by the development of 
tolerance.  
Ratings of satiation did not differ significantly among the groups, which was 
surprising in light of evidence that sibutramine precipitates the satiation process (e.g.,  
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Figure 3. Mean changes (mm) in cravings from baseline during 18 weeks of treatment in 
 
the three groups. 
 
 
 
meal size is reduced following administration of the drug) (Chapelot et al., 2000). There 
was, however, a significant difference in scores collapsed across the groups at week 3 
compared with week 6, and at week 6 compared with week 18. As shown in Figure 4, 
satiation ratings decreased significantly (thus, appetite control worsened) from week 3 to 
week 6, and then increased significantly (thus, appetite control improved) from week 6 to 
week 18. This response pattern suggests that during 18 weeks of treatment, regardless of 
modality, patients may feel less satiated during the first few weeks of the intervention, 
before experiencing an increase in fullness thereafter.  
Interestingly, satiation scores among subjects treated with combined therapy and 
behavior therapy alone remained slightly below their baseline levels at week 18, despite 
their improvements from week 6 (see Figure 4). By contrast, the ratings among those 
treated with sibutramine alone remained above baseline for the majority of treatment.  
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Figure 4. Mean changes (mm) in satiation from baseline during 18 weeks of treatment in  
 
the three groups. 
 
 
 
Caution must be used when interpreting these results because of the absence of 
significant differences in satiation scores among the groups. However, these data suggest 
that those treated with medication alone experienced a greater sensation of fullness, and 
thus better appetite control, than those treated with either combined therapy or behavior 
therapy alone. The discrepancy in scores between the sibutramine alone and combined 
therapy groups is puzzling, as we would expect satiation ratings to increase in both 
conditions as a result of the medication. Patients who received combined therapy lost 
significantly more weight than those who received sibutramine alone in the original trial 
(see Figure 1). It is possible that greater compensatory metabolic and hormonal changes 
(Brownell, 2010), resulting from the greater weight loss achieved with combined therapy, 
attenuated the effects of the medication and, thus, led to a lesser sensation of fullness 
among these subjects. By comparison, these biological forces may have exerted less 
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influence on the satiation levels of those treated with medication alone because of their 
smaller weight losses. 
Although hunger ratings among the three groups were in the expected directions, 
the differences in scores were not statistically significant (see Figure 5). This outcome is 
surprising since we expected a greater suppression of hunger among those treated with 
sibutramine than with behavior therapy. Perhaps the effects of the medication on hunger 
levels were not sufficiently robust for subjects to notice. Two controlled laboratory 
studies have suggested that the subjective effects of sibutramine may be subtle. Chapelot 
et al. (2000) found that acute sibutramine (15 mg) treatment decreased total daily energy 
intake by approximately 14% in a group of lean men. Rolls, Shide, Thorwart, and 
Ulbrecht (1998) found that maintenance on 10 and 30 mg of sibutramine decreased total 
daily energy intake by up to 23% in a group of obese women. In both studies, sibutramine 
produced only minimal effects on subjective ratings of hunger, despite the observed 
reductions in energy intake.  
Another potential explanation for the lack of group differences in hunger scores 
relates to the pharmacokinetics of sibutramine. Peak plasma concentrations of the active 
sibutramine metabolites (i.e., active metabolites 1 and 2) are reached 3 to 4 hours after a 
single dose of sibutramine (15 mg) (Garratt, Hind, & Haddock, 1995). Findings 
show that hunger ratings begin to decrease 240 minutes (or 4 hours) after administration 
of the drug and that the medication exerts its most potent action on energy intake at 
lunchtime (following morning administration) (Chapelot et al., 2000). Patients treated 
with sibutramine in the current study were required to take the medication in the morning  
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Figure 5. Mean changes (mm) in hunger from baseline during 18 weeks of treatment in 
 
the three groups.  
 
 
 
and to complete the visual analogue scales, like all subjects, on-site in the evening. It is 
possible that their hunger scores corresponded with the lower plasma concentrations of 
the medication at the time they completed the scales and, therefore, captured subjects 
while their hunger was being less suppressed by the drug. Had these subjects completed 
the scales at lunchtime, concomitant with the estimated plasma peak of active metabolites 
1 and 2, we may have found a significant difference in hunger scores compared with 
those of subjects who did not receive the drug.   
The lack of group differences in hunger scores also may be attributable to the 
effects of exercise. Although the impact of exercise on appetite remains unclear (Martins, 
Morgan, & Truby, 2008), research has shown a reduction in hunger and a decrease in 
energy intake after moderate exercise in both obese and nonobese men (Westerterp-
Plantenga, Verwegen, Ijedema, Wijckmans, & Saris, 1997). Vigorous exercise (high-
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intensity cycling or running) also has been shown to reduce hunger significantly (King, 
Burley, & Blundell, 1994). Patients who received behavior therapy in the current study 
were prescribed specific exercise goals (e.g., walk for 30 minutes per day, most days of 
the week), which were closely monitored and reviewed during group sessions. As shown 
in Figure 5, patients treated with behavior therapy alone reported feeling less hungry 
throughout treatment, which may be attributable in part to their having increased their 
physical activity as prescribed. Their reductions in hunger may have reduced our power 
of detecting significant differences in hunger scores among the groups.  
Finally, subjects may have become tolerant to the suppressive effects of 
sibutramine on hunger during the course of the trial, which also would have reduced our 
power of detecting group differences in hunger scores. As shown in Figure 5, subjects 
who received sibutramine alone reported an increase in hunger from week 3 to week 6, 
after which their hunger subsided in accordance with being prescribed 15 mg of the drug 
(at week 6). However, hunger ratings increased again from week 10 to week 18. One 
might argue that these subjects became tolerant to each dose of the medication over time, 
which potentially could explain their progression of scores and their failure to achieve 
better hunger control than those treated with behavior therapy alone. However, because 
those who received combined therapy failed to display a similar response pattern to that 
of those who received medication alone, it appears unlikely that the subjects’ ratings were 
affected by the development of tolerance.    
In total, although we failed to find significant differences across all measures of 
appetite, most of our findings were in the expected direction and corresponded with our 
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original hypotheses. Patients who received sibutramine alone reported more fullness and 
less food preoccupation, fewer cravings, and reduced hunger. They did not display a 
significant increase in weight control behaviors. By contrast, those who received 
behavior therapy alone reported less fullness and more food preoccupation and cravings. 
However, these patients did show a significant increase in weight control behaviors. 
Patients treated with combined therapy reported improvements in both appetite control 
and eating behavior. They reported reductions in food preoccupation, cravings, and 
hunger, along with a significant increase in weight control behaviors. Thus, the greater 
weight loss achieved with combined therapy in the original trial may be attributed to the 
complementary mechanisms of action of each approach, as suggested by Wadden, 
Berkowitz, et al. (2005). Sibutramine appeared to modify subjects’ internal environment 
related to appetite, while behavior therapy appeared to modify their external environment 
related to food. Used together, these therapies appeared to address a greater number of 
variables than when used separately, which consequently led to greater weight loss. Our 
results are significant in that they provide evidence for the additive effects of sibutramine 
and behavior therapy. 
After the current study was completed, the FDA requested that Abbott 
Laboratories – the manufacturer of sibutramine (branded as Meridia in the United States) 
– voluntarily withdraw the drug from the market, based on data from the Sibutramine 
Cardiovascular Outcomes Trial (SCOUT) (James et al., 2010). The SCOUT study was a 
randomized, placebo-controlled, multicenter trial, conducted between January 2003 and 
March 2009, which sought to demonstrate the long-term health benefits of weight 
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management with sibutramine plus lifestyle modification. The sample consisted of 
approximately 10,000 subjects, aged 55 years or above, with a BMI between 27 and 45 
kg/m
2
, or between 25 and 27 kg/m
2
 with an increased waist circumference. Subjects were 
required to have a history of cardiovascular disease (i.e., coronary artery disease, stroke, 
or occlusive peripheral arterial disease) and/or type 2 diabetes with at least one other 
cardiovascular risk factor (i.e., hypertension, dyslipidemia, current smoking, or diabetic 
nephropathy). Results showed a 16% increase in risk of major adverse cardiovascular 
events (which were a composite of nonfatal myocardial infarction, nonfatal stroke, 
resuscitation after cardiac arrest, and cardiovascular death) in patients treated with 
Meridia compared with those treated with placebo. At the end of the trial (60 months), 
the difference in mean percent change in body weight between the Meridia and placebo 
groups was only 2.5%. Based on these results, the FDA concluded that the risk of an 
adverse cardiovascular event from Meridia outweighed any benefit from the modest 
weight loss observed with the drug. Abbott Laboratories agreed to remove Meridia from 
the market in October 2010. 
The results of the current study still have significant implications on clinical 
practice, in spite of the recent withdrawal of sibutramine. A number of medications 
remain on the market for the short-term treatment of obesity, such as phentermine, 
diethylpropion, and phendimetrazine. These agents generally affect the availability of 
serotonin, norepinephrine, and/or dopamine in the central nervous system, which in turn 
suppresses appetite (Huizinga, 2007). Orlistat, a gastric and pancreatic lipase inhibitor 
that reduces the absorption of dietary fat, also remains approved for the long-term 
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management of obesity. Current guidelines recommend that weight loss medications be 
used as an adjunct to a comprehensive program of diet, exercise, and behavior therapy 
(NHLBI, 1998). The results of the original trial confirm that significant weight loss 
occurs with this approach (Wadden, Berkowitz, et al., 2005), and we have shown this 
outcome to be attributable to the complementary mechanisms of action of 
pharmacotherapy and behavior therapy. Unfortunately, weight loss medications often are 
prescribed by physicians in the absence of lifestyle counseling (Blanck, Kahn, & Serdula, 
2004; Phelan & Wadden, 2002).  
In fact, surveys indicate that fewer than one half of obese patients are counseled 
by their physicians about losing weight and that these rates are actually declining 
(Jackson, Doescher, Saver, & Hart, 2005; McAlpine & Wilson, 2007). Data from the 
1995 to 2004 National Ambulatory Medical Care Survey (NAMCS) – an annual national 
survey of visits to office-based physicians – show that obesity-related counseling 
occurred in only 25.3% of office visits in 1995-1996 and dropped to 24% in 2003-2004 
(McAlpine & Wilson, 2007). Findings from the Behavioral Risk Factor Surveillance 
System (BRFSS) – an annual telephone survey conducted by all states, the District of 
Columbia, and Puerto Rico – indicate that 44% of patients received weight loss advice 
from their physicians in 1994, compared with only 40% in 2000 (Jackson et al., 2005).  
Numerous barriers appear to exist in the provision of lifestyle counseling by 
physicians. In a national survey of physicians’ attitudes towards obesity and its treatment, 
Foster et al. (2003) found that more than one half of the 620 respondents reported that 
they would spend more time providing weight management services if their time were 
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reimbursed appropriately. Lack of reimbursement, therefore, appears to be a key obstacle 
to providing obesity-related counseling. Physicians also rated lack of physical activity as 
being significantly more important than any other cause of obesity, followed by 
overeating and the consumption of a high-fat diet. Nearly one half of respondents rated 
psychological problems as very or extremely important causes of obesity. These data 
suggest that physicians may view obesity primarily as a behavioral as opposed to a 
biological or genetic problem. Given that their training traditionally has emphasized the 
biological management of disease, physicians may feel ill-equipped to manage obesity 
effectively. Indeed, only 14% of respondents believed that they were usually successful 
in helping patients lose weight. 
Foster et al. (2003) also found that physicians tend to view obesity treatment as 
ineffective. Less than 50% of respondents felt that it was possible for obese patients to 
lose a significant amount of weight, and only 22% believed that maintaining weight loss 
was possible in the long term. Moreover, physicians rated the treatment of 9 out of 10 
chronic conditions (including but not limited to hypertension, diabetes, and coronary 
artery disease) as significantly more effective than the treatment of obesity. Leverence et 
al. (2007) recently substantiated these findings, indicating that the perceived 
ineffectiveness of treatment contributes to physicians’ reluctance to provide weight loss 
counseling.  
Furthermore, Foster et al. (2003) found that physicians, much like the general 
population (Grilo, 2006), tend to hold critical views of obese patients. More than one half 
of respondents viewed these patients as awkward, unattractive, ugly, and noncompliant, 
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and approximately one third characterized them as weak willed, sloppy, or lazy. Prior 
studies have shown that the heavier the patient, the more negative the attitudes and 
distancing behaviors are of physicians (Harvey & Hill, 2001; Hebl & Xu, 2001). 
Therefore, in addition to the lack of reimbursement, the perception of obesity as a 
behavioral or psychological problem, and the belief that obesity treatment is ineffective, 
it is possible that physicians are reluctant to provide lifestyle counseling to obese patients 
as a result of their negative attitudes toward these individuals. Such attitudes were 
discovered decades ago (Maddox & Liederman, 1969) and, unfortunately, appear to 
persist today. 
The challenges that physicians face when treating obese patients potentially can 
be overcome through the integration of behavioral health providers (BHPs) within 
primary-care settings (Hunter, Goodie, Oordt, & Dobmeyer, 2009; Tsai, Carvajal, Egner, 
& Wadden, 2010). Many common medical conditions, such as obesity, involve 
maladaptive behaviors that initiate, exacerbate, or maintain symptoms. Modifiable 
behavioral factors (e.g., poor diet, lack of physical activity) are found to be the leading 
causes of chronic health problems and mortality in the United States (APA, 2009). 
Currently, physicians, physician assistants, and nurse practitioners provide the majority 
of behavioral health services in primary care (Hunter et al., 2009). The aforementioned 
obstacles to the delivery of these services, however, may compromise the standard of 
care provided to patients. In addition, these providers, while qualified to deliver physical 
medicine, often lack the appropriate training in lifestyle counseling (Hunter et al., 2009). 
Evidence shows that while low- to moderate-intensity physician counseling for obesity 
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(i.e., fewer than two visits per month), without pharmacotherapy, fails to yield clinically 
significant weight loss, more intensive counseling provided by nonphysician personnel 
may help patients achieve this goal (Tsai & Wadden, 2009). BHPs who specialize in 
lifestyle modification, therefore, can be used to provide these services in place of medical 
personnel. The integration of BHPs within primary care would reduce the burden on 
physicians to provide all acute, chronic, and preventive services for their patients (Frank, 
1998; Yarnall, Pollak, Ostbye, Krause, & Michener, 2003) and would enable physicians 
to focus primarily on the biological management of obesity while allocating the 
behavioral management to BHPs located within the practice.        
From a broader perspective, the APA recently has advocated for the integration of 
psychologists and other mental health providers within primary care and other health care 
settings, including specialized medical centers, long-term care settings, and community-
based health and social service organizations (APA, 2008, 2009; Clay, 2010). Integrated 
health care (also known as interdisciplinary health care) is an approach to clinical 
practice that is characterized by a high degree of collaboration and communication 
among a diverse team of health care professionals (APA, 2008). Members of the team 
may include physicians, psychologists, social workers, occupational and physical 
therapists, and other specialists, depending on the needs of the patient. Information 
related to patient care is shared among members in an effort to develop a comprehensive 
treatment plan that addresses the complete biological, psychological, environmental, and 
sociocultural needs of the patient, thereby improving the standard of care of patients. 
Findings show that integrated health care enhances access to services, improves quality 
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of care, and lowers overall health care expenditures, and the APA considers its delivery a 
top priority for national health care reform (APA, 2008, 2009; Clay, 2010).  
In accordance, Hunter et al. (2009) recently developed a five-step, patient-
centered model of obesity counseling for BHPs who are integrated within primary-care 
settings. The five steps, known as the 5A’s, are Assess, Advise, Agree, Assist, and 
Arrange. The 5A’s format has been strongly recommended for assessing and treating a 
variety of behavioral health concerns in primary care, including obesity (Goldstein, 
Whitlock, & DePue, 2004; Simkin-Silverman & Wing, 1997). The specific interventions 
at each stage are based on treatment guidelines issued by the NHLBI (1998) and are 
designed to help patients develop a self-manageable weight loss plan, with the assistance 
of the primary-care team. We conclude this discussion by presenting an overview of the 
model in order to provide BHPs with an empirically based option for treating obesity in 
primary care. More information about the model can be found in Hunter et al. (2009).  
In the first stage – Assess – the BHP measures patients’ BMI and collects 
information about their weight history, including patterns of weight loss and weight gain. 
Information from their weight history is used to establish their learning history related to 
weight, which the BHP can later use to develop personalized recommendations for 
weight loss. This stage also includes an assessment of patients’ thoughts associated with 
weight loss, which can help the BHP to determine patients’ self-efficacy with respect to 
losing weight. Patients’ thoughts about losing weight also can provide a measure of their 
motivation and readiness to change, areas that can have significant implications on 
treatment (Hawkins, Hornsby, & Schorling, 2001; Simkin-Silverman & Wing, 1997; 
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Smith, Heckemeyer, Kratt, & Mason, 1997). Finally, the BHP assesses patients’ eating 
behaviors, such as their food and beverage choices, speed and frequency of eating, and 
times and places associated with eating. Patients who display symptoms of an eating 
disorder, such as binge-eating and/or purging, may be referred to specialty care. 
 During the Advise stage, the BHP informs patients about the medical benefits of 
losing weight and highlights the benefits associated with a modest weight loss (i.e., 5 to 
10% of initial weight). Patients also are educated on the importance of losing weight 
slowly (e.g., 1 to 2 pounds per week) as a means of producing a safe, sustainable weight 
loss. Those who are prescribed weight loss medications or who are attending commercial 
weight loss programs are encouraged to continue these treatments if they find them 
helpful. However, they are informed that regular follow-up appointments with the BHP 
may help to maximize their success.  
Hunter et al. (2009) conceptualize the Agree stage as a bridge between the Assess 
and the Assist stages, wherein the BHP determines if patients are interested in losing 
weight and in developing a weight loss plan. While many patients have a strong desire to 
lose weight, they tend to be ambivalent about modifying their lifestyle as a result of their 
past difficulties or relapse experiences (Simkin-Silverman & Wing, 1997). Therefore, the 
BHP uses motivational interviewing techniques, such as open-ended questions, reflective 
listening, and affirmation, in order to increase patients’ motivation for change. The BHP 
explores patients’ ambivalence in a nonconfrontational manner, encourages them to 
express their arguments for change, and helps them resolve their ambivalence through the 
development of self-motivational statements (Miller & Rollnick, 2002). Such techniques 
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have been shown to improve adherence to weight loss programs (Simkin-Silverman & 
Wing, 1997; Smith et al., 1997).  
Formal intervention occurs during the Assist stage, wherein the BHP helps 
patients reduce their energy intake and increase their physical activity in order to lose 
weight. Principal interventions include goal setting, calorie education, and behavior-
change planning. Consistent with recommendations of the NHLBI (1998), patients are 
encouraged to lose 1 to 2 pounds per week, with the goal of losing and maintaining 10% 
of their initial body weight. They are encouraged to reduce their intake of calorie-dense 
foods and increase their intake of fruits, vegetables, and whole grains. Patients also are 
instructed to monitor their food intake through the completion of food records. Finally, 
they are encouraged to make healthful changes to their eating and physical activity, such 
as reducing portion sizes, eating on a schedule, storing high-calorie foods out of sight, 
and gradually increasing the amount of walking.   
In the final stage – Arrange – the BHP develops a follow-up plan with patients, 
including when and how often future sessions will take place. These sessions are used to 
assess progress, address any lapses in weight, and reinforce healthful behaviors and/or 
introduce new skills related to weight control. Typically, the BHP meets with patients on 
a weekly basis in order to monitor progress and resolve any barriers to adherence. 
Sessions are then tapered down (e.g., from weekly to monthly) when patients display 
adequate control of their weight. The BHP aims to help patients follow a plan that they 
can self-manage in the long term, with the assistance of the primary-care team. Patients 
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who fail to lose weight with primary-care intervention may be referred to specialty care, 
such as a comprehensive behavioral weight loss program.  
The current study has allowed us to identify the mechanisms of action responsible 
for the greater weight loss associated with combined therapy than with either therapy 
alone. However, our study is not without limitations. First, appetite ratings were made in 
retrospect (e.g., “How hungry have you felt over the past 24 hours?”) and, as such, may 
have been subject to retrospective distortion. These ratings also provided a measure of 
subjective appetite, which can be influenced by a variety of factors. Appetite, for 
example, tends to vary in response to variations in patients’ work or social activities 
(Womble et al., 2003). External factors, such as prior meals, physical activity, 
temperature, and weather, also may affect appetite (Flint et al., 2000). These events may 
afford or eliminate opportunities to eat, including what and how much food is eaten. 
Therefore, while some patients may view appetite as a trait characteristic, appetite is very 
much state dependent and changes in response to social and environmental cues (Womble 
et al., 2003). The design of our study did not allow us to control for these factors. Our 
study also included a relatively high ratio of female to male subjects. Studies with 
nonhuman primates (Foltin, 2006) and with rats (LeBlanc & Thibault, 2003) found that 
females were more responsive to the anorectic effects of sibutramine. Owing to the 
gender composition of our sample, our findings may not generalize adequately to the 
male population. More broadly, the original trial was conducted at an academic medical 
center and may well have included patients who were not representative of the general 
population. This is a common limitation among studies on obesity treatment (Wadden & 
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Butryn, 2003). Study volunteers often are more motivated to lose weight, as evidenced by 
their willingness to participate in clinical research trials. Our ability to generalize our 
results to the population at large thus may be compromised by this sample restriction.   
Future investigations should examine the short- and long-term efficacy of 
combining behavior therapy with medications that are approved at present for the 
management of obesity. A number of new agents are currently under development, 
including combination drugs such as phentermine-topiramate and naltrexone-bupropion 
(Tsai et al., 2010). If approved, the efficacy of these drugs ought to be examined in 
combination with behavior therapy as well. Studies should also explore, in humans, the 
potential role of sex in moderating the effects of anorectic medications. The results of 
these studies would allow investigators to better match patients to particular drugs, 
whether used singularly or combined with behavior therapy, as to produce the best 
outcomes (Phelan & Wadden, 2002). Research also should focus on developing 
behavioral techniques that better address the elevations in food preoccupation and 
cravings that appear to accompany behavior therapy, as was shown in the current study. 
Findings have suggested that poor control of food preoccupation (Timmerman & Gregg, 
2003) and cravings (Ferguson, Brink, Wood, & Koop, 1992) can impair weight control. 
Thus, patients likely would benefit from learning more effective ways to manage these 
events. Finally, future investigations on the additive effects of pharmacotherapy and 
behavior therapy should assess changes in appetite under a set of standardized conditions, 
similar to that utilized in prior studies of appetite (Chapelot et al., 2000; Flint et al., 2000; 
Rolls et al., 1998). For example, patients might be asked to rate their appetite before 
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consuming a fixed-calorie test meal and then every 30 minutes during a scheduled 
postprandial period under the same conditions, while their energy intake is covertly 
measured by investigators (e.g., via weighing food items before and after consumption). 
Such a design would allow for a more controlled comparison of appetite between 
different treatment conditions.  
Obesity has reached epidemic proportions in the United States. Interventions that 
make the management of weight easier and more sustainable clearly are needed in order 
to improve the health of millions. Recently, the combination of sibutramine and behavior 
therapy has been found to produce greater weight loss than either therapy alone. We have 
expanded on this finding by providing evidence that sibutramine and behavior therapy, 
through their complementary mechanisms of action, work additively to produce this loss. 
Our findings underscore the importance of prescribing weight loss medications in 
conjunction with lifestyle modification. Unfortunately, physicians face many obstacles in 
providing lifestyle counseling to obese patients. The integration of BHPs within primary-
care settings would reduce this burden on physicians and afford patients access to obesity 
counseling within the practice. Such an integrated approach to obesity management likely 
would improve the quality of care and subsequent health of obese patients. 
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